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ABSTRACT OF THE DISSERTATION 
 
 
 
Coffee Consumption, Smoking, and Genetic Factors of  
Parkinson’s Disease: Gene-Environment Interaction and  
Genome-wide DNA Methylation Studies 
 
by 
 
 
 
Yu-Hsuan Chuang 
 
Doctor of Philosophy in Epidemiology 
 
University of California, Los Angeles, 2017 
 
Professor Beate R. Ritz, Chair 
 
 
 
 
 
Parkinson’s disease (PD) is a common neurodegenerative disorders with a complex and 
unclear etiology in which both environmental and genetic factors contribute to disease. Over the 
past decade, gene-environment interaction and DNA methylation association studies have been 
used to explore the biological mechanisms underlying PD in order to help develop new strategies 
for prevention and treatment.  
Drinking caffeinated coffee has been reported to protect against PD. Caffeine is an 
adenosine A2A receptor (ADORA2A) antagonist that increases dopaminergic neurotransmission 
and Cytochrome P450 1A2 (CYP1A2) metabolizes caffeine. In a population-based case control 
study in Denmark (PASIDA), we estimated statistically significant interactions for ADORA2A 
rs5760423 and heavy vs. light coffee consumption in incident (OR interaction=0.66 [0.46-0.94], 
p=0.02) but not prevalent PD. In meta-analyses combining data from a large consortium study 
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(PEGASUS), PD associations with daily coffee consumption were strongest among carriers of 
variant alleles in both ADORA2A and CYP1A2.  
There has also been growing interest in investigating whether inflammation-related genes 
interact with environmental factors such as smoking to influence PD risk. We replicate the 
previously reported inverse association human leukocyte antigen (HLA)-DRB1 rs660895 and the 
risk of PD in the Danish PASIDA study. Moreover, both in the Danish study and in the pooled 
analysis combining two French studies (Terre and Partage), sub-multiplicative interactions were 
observed between rs660895 and smoking (OR interaction=1.54, p=0.001), such that the inverse 
association of rs660895-G with PD decreased among smokers. 
Lastly, we investigated whether epigenetics play a role in health benefits of drinking 
coffee. We associate epigenome-wide DNA methylation levels to habitual coffee consumption 
from two studies with blood (Parkinson’s Environment and Gene (PEG wave 1) and Women’s 
Health Initiative), and one with saliva samples (PEG wave 2) using bi-weighted mid-correlation 
and meta-analysis. Adjusting for age, gender, and blood cell composition, one CpG (cg21566642 
near ALPPL2) surpassed genome-wide significance (p = 3.7x10
-10
) and from among ten 
additional CpGs significant at p≤5.0x10-6. These CpGs are found in or near genes related to lipid 
metabolism and immune response. Interestingly, when we stratified by menopausal hormone 
therapy, methylation differences with coffee consumption were observed only in women who 
never used MHT. We did not replicate any of the associations found in blood in our saliva 
samples. 
Overall, my dissertation provides epidemiologic and biological evidence supporting the 
hypotheses that caffeine plays a biological role in reducing PD risk and may have beneficial 
iv 
 
effects in chronic disease or other neurodegenerative disorders. More importantly, 
neuroinflammation is an important contributor to the pathogenesis of PD. 
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1. Background and Introduction 
 
1.1 Dissertation Objectives 
 
The aim of this dissertation is to investigate whether lifestyle factors i.e. coffee 
consumption and smoking, play biological roles in the etiology of PD. If the previously reported 
associations cannot be explained by bias, we would like to know how they interact with genetic 
factors and what possible mechanisms are in order to cause PD. We also aim to investigate the 
influence of coffee consumption on DNA methylation levels, which is believed to act as a 
potential mediator for caffeine’s influence on health, including PD. Briefly, the first project 
examines the interaction of coffee consumption with the ADORA2A and CYP1A2 polymorphisms 
in modifying PD risk, and whether this interaction is different between prevalent vs. incident PD 
cases. The second project examines the association of HLA-DRB1 polymorphisms with PD, and 
whether smoking and the HLA-DRB1 polymorphisms act together to influence the risk of PD. 
The third project investigates the association of coffee consumption and DNA methylation sites 
from a genome-wide screen in human blood, as well as in saliva. 
 
1.2 Parkinson’s disease background 
 
Parkinson’s disease is the second most common neurodegenerative disorder with a 
prevalence of 0.5-1% among people more than 65 years of age (Tanner et al. 1996). Each year 
60,000 new cases are identified in the US, and by 2017, over 10 million people worldwide live 
with PD (Parkinson's Disease Foundation 2017). PD’s  four cardinal features include resting 
tremor, bradykinesia, rigidity, and postural instability, and they are attributed to the effects of a 
loss of dopaminergic neurons in substantia nigra pars compacta (Hoehn et al. 1967). However, 
PD is hard to accurately diagnose at the early stages for the following reasons: 1) the 
characteristic motor symptoms do not develop until 50-60% of the dopaminergic neurons are lost 
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and 80-85% of the dopamine is depleted in striatum; 2) other disorders such as postencephalitic, 
drug-induced, and arteriosclerotic parkinsonism share the symptoms and signs of PD. Currently, 
the most commonly used clinical criteria for PD diagnosis are the United Kingdom Brain Bank 
and Gelb criteria (Hughes et al. 1992; Gelb et al. 1999). People with the presence of at least two 
of the four cardinal features are considered as PD patients.  
Epidemiologic studies have shown that age over 60, male gender, Hispanic/non-Hispanic 
white, and family history of PD are associated with a higher risk of PD (Van Den Eeden et al. 
2003; Wirdefeldt et al. 2011). Although approximately 5-10% of PD is familial and appears to 
follow autosomal dominant inheritance, familial aggregation is stronger for early-onset cases 
than late-onset cases. Over 90% of PD patients are considered “idiopathic” without known 
genetic causes; it is likely that a combination of genetic and environmental factors together 
contribute to the disease. Lifestyle factors such as coffee consumption and smoking have been 
consistently associated with a decreased the risk of PD, with some study showing in women the 
protective effect of caffeine may be attenuated by estrogen use (Ascherio et al. 2004; Palacios et 
al. 2012). But some argue that the significant inverse association between coffee or smoking and 
PD can be explained by different systemic biases, such as reverse causation, competing risk, and 
confounding. For instance, PD patients may have changed coffee drinking behavior (e.g. tend to 
stop drinking coffee due to prodromal symptoms -- loss of smell or insomnia) or changed 
smoking habits (e.g. less prone to smoke or more likely to quit due to less sensitive nicotinic 
response) in the preclinical period of PD, thus a possibility of reverse causation cannot be ruled 
out. Furthermore, compared to non-smokers, smokers have a higher mortality of lung cancers, 
heart disease or other smoking-related diseases. We may observe less prevalent PD cases among 
smokers than non-smokers if smokers die earlier. 
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During the past decade, genome-wide association studies (GWAS) have been widely used 
to identify genes for idiopathic PD in a hypothesis-free manner. A recent meta-analysis of 
GWAS replicated associations with 24 previous identified single nucleotide polymorphisms 
(SNPs) and proposed 6 additional SNPs as risk variants for PD (Nalls et al. 2014). As expected, 
most SNPs contribute only weakly to population risk (OR<1.3) of PD, in spite of the fact that six 
SNPs further showed associations with gene expression or DNA methylation. Exploring gene-
environment interaction and DNA methylation association may help understand the biologic 
mechanisms of PD and suggest helpful biomarker for PD prevention and treatment. 
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2.   Gene-Environment Interaction in Parkinson’s Disease: Coffee, ADORA2A, and 
CYP1A2 
2.1 Introduction 
More than 90% of Parkinson’s disease (PD) is considered to be “idiopathic” – with 
genetic and environmental factors increasing risk of disease. A protective effect of coffee on PD 
has been postulated since many epidemiologic studies reported lower consumption of caffeinated 
coffee among PD patients (Nefzger et al. 1968; Hellenbrand et al. 1996). Ever vs. never drinkers 
have a 30% lower risk of PD and three additional cups of coffee per day lowered PD risk on 
average by 25-32% (Hernan et al. 2002). Caffeinated coffee is a very popular beverage in 
Northern European countries, especially Denmark, and we recently reported a 55% lower risk of 
PD  among moderate coffee drinkers in Denmark (Kenborg et al. 2015). A landmark early 
prospective cohort study not only reported an inverse association for coffee, but also for caffeine 
from non-coffee sources, suggesting it might be the protective agent(Ross et al. 2000). This 
association was replicated in many prospective cohort and case-control studies and further 
strengthened by observations of exposure-response trends (Hernan et al. 2002; Saaksjarvi et al. 
2008; Qi et al. 2014). Animal studies lent additional support to the idea that caffeine and its 
metabolites are neuro-protective (Xu et al. 2010). Yet, the biological mechanisms underlying 
neuroprotection derived from caffeine have yet to be established. Importantly, epidemiologic 
data – even from prospective studies - do not preclude reverse causality since those who later 
develop PD may stop drinking caffeinated coffee due to sleep disorders, anxiety, gastro-intestinal 
problems or simply a loss of smell that could make coffee drinking less enjoyable in the very 
long pre-motor stages of PD. Evidence for interactions between caffeinated coffee and genes that 
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metabolize caffeine or encode brain receptors targeted by caffeine, could help strengthen 
arguments that caffeine indeed plays a biological role in reducing PD risk.  
Recently, a large consortium (PEGASUS) combined data from 1,325 PD cases and 1,735 
controls and reported that PD risk was influenced by interactions between the single-nucleotide 
polymorphisms (SNP) rs5751876 and rs3032740 in ADORA2A, which encodes the adenosine 
A2A receptor in dopamine neurons, and caffeinated coffee consumption (Popat et al. 2011); 
however, two much smaller studies did not find evidence for such interaction (Tan et al. 2006; 
Facheris et al. 2008). In addition, the PEGASUS study also observed stronger coffee-PD 
associations among carriers of the CC genotype of rs762551 in CYP1A2 compared with CA or 
AA carriers (Popat et al. 2011), a gene that encodes the cytochrome P450, family 1, subfamily A, 
polypeptide 2, the main caffeine metabolizing enzyme.  
 Relying on data from a large population-based case control study of PD (“Parkinson’s 
Disease in Denmark” [PASIDA]), here we re-examine interactions of coffee consumption with 
ADORA2A and CYP1A2 polymorphisms and also assess whether reliance on prevalent versus 
incident PD cases influences results, a distinction that may have caused previous study results to 
disagree (Hill-Burns et al. 2011). 
 
2.2 Materials and Methods 
The PASIDA study was approved by the Institutional Review Boards of UCLA, the Danish Data 
Protection Agency, and the ethics committee of Copenhagen. Informed consent was obtained 
from all study participants 
 
Study population 
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The PASIDA study enrolled idiopathic PD patients (ICD-8 342 and ICD-10 G20) treated 
at 10 neurological treatment centers and identified from the Danish National Hospital Register 
between 1996 and mid-2009 with subsequent validation of their diagnoses by medical record 
review. Population controls, free of PD when matched cases were diagnosed, were selected from 
the Danish Central Population Registry (individually matched on year of birth and sex). Detailed 
recruitment information was published  previously (Kenborg et al. 2015). Of 3,700 recruited 
subjects, 1,575 (87%) PD cases and 1,607 (85%) controls provided DNA samples (saliva) for 
genotyping. We further excluded subjects who were diagnosed with dementia prior to interview, 
leaving 1,556 PD cases and 1,606 controls for analyses. 
Exposure assessment and variable definition 
Standardized telephone interviews were conducted between 2008 and 2010 to obtain 
participants’ lifetime caffeinated coffee consumption history (drip- and instant-coffee) and 
information on other lifestyle factors. Due to the high prevalence (> 90%) of caffeinated coffee 
drinking in Denmark but little tea and caffeinated soda consumption during the study period, we 
omitted the latter caffeine sources.  We collected lifetime amount and duration of caffeinated 
coffee-drinking, asking participants to report start and stop ages and the average number of cups 
the consumed per day. We consider an ‘ever’ coffee drinker someone who consumed at least one 
cup (6 oz) of coffee per week for a year. To obtain the amount of caffeine intake, we converted 
coffee cups per day into daily caffeine consumption (mg) using the U.S. Department of 
Agriculture criteria (Gebhardt et al. 2000). Only consumption before the index date contributed 
to our exposure measures, i.e. the date of first motor symptom recorded on the medical record, or 
the date of PD diagnosis for both cases and their matched controls.  
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Genotyping 
DNA was extracted from saliva using standard protocols. Samples were genotyped on the 
QuantStudio™ 12K Flex Real-Time PCR System using multiplex Taqman allelic discrimination 
assays (Applied Biosystems) according to the manufacturer’s protocol. Each 384-well plate 
included ~5% HapMap CEU samples genotyped in duplicates across plates to assess genotyping 
accuracy. To control for genotyping quality, we excluded samples with genotyping efficiency 
less than 80% and SNPs with low genotyping efficiency (<95%) and accuracy (<99.5%); all 
three SNPs (rs5760423, rs762551, rs2472304) in this study met these criteria. 
Statistical Analysis 
We tested for deviation from Hardy-Weinberg Equilibrium among controls using 
Pearson’s chi-square test (all p ≥ 0.05). We broke the matched pairs and conducted unconditional 
logistic regression analyses adjusting for sex, birth year, and onset/index age to estimate 
marginal associations between caffeinated coffee consumption and PD status as well as between 
the three ADORA2A or CYP1A2 polymorphisms and PD status (additive genetic model), 
respectively. We broke the  matched sets  to avoid loss of entire pairs with only one subjects 
when conducting stratified analyses and to increase efficiency since many pairs shared the same 
matching variable values (Kenborg et al. 2015). However, we compared the overall results from  
conditional with the results from unconditional logistic regression adjusted for all of the 
matching variables and found them to be identical. Matching variables (i.e., year of birth, gender 
and onset/index age), potential confounders (i.e., any kind of tobacco smoking) and strong 
predictors of PD (i.e., family history) were included in all models. We treated coffee intake as a 
binary variable with light vs. heavy consumption (defined as 0 to <= median vs. > median cup-
years (Hill-Burns et al. 2011)) and also as a continuous variable (number of cups per day). We 
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further created categories of caffeine intake in mg per day and years of coffee consumed using 
category definitions from our previous paper (Ahmed et al. 2014). The Wald test for trend was 
applied to categorized coffee variables testing for a linear relationship with PD. Information 
about ethnic diversity was not available but based on demographics of the Danish population 
provided by Denmark we are confident that the large majority were non-Hispanic Whites(2015). 
We used multiplicative terms in logistic regression adjusted for confounders to assess 
whether the ADORA2A or CYP1A2 polymorphisms modify caffeine-PD associations and  the 
likelihood ratio chi-square tests was used to evaluate statistical significance . We also restricted 
all analyses to incident PD patients and their matched controls, i.e. those diagnosed close to their 
date of interview during 2006-2009, to assess whether survival or recall bias may have 
influenced results with prevalent patients. Analyses were conducted using SAS version 9.4 (SAS 
Institute, Inc., Cary, North Carolina). 
Lastly, we conducted meta-analyses to aggregate results from PASIDA (incident cases 
only) and non-Hispanic Whites from PEGASUS (Popat et al. 2011), based on  type of PD case  
(i.e. incident), control selection (i.e. population-based controls) and ethnicity (i.e. non-Hispanic 
Whites) using the metagen package in the R environment , which allows to fit fixed-effects and 
random- effects models (Friedrich 2013). In the meta-analysis, results of ADORA2A rs5760423 
in PASIDA were equated with rs5751876 in PEGASUS because they are in high linkage 
disequilibrium (LD) (Byrne et al. 2012); also we combined our coffee category of ‘heavy use’ 
with ‘ever’ consumption in PEGASUS as well as and ‘light’ consumption in PASIDA with 
‘never’ in PEGASUS since less than 10% of PASIDA participants reported having never 
consumed coffee.  
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2.3 Results 
Our initial analysis included 3,162 Danish participants in the PASIDA study with high-
quality genotyping data. The average age of PD onset or index age was 61 years for all 
participants (Table 2-1) and 64 years for incident PD patients and their-matched controls only. 
Sixty percent of participants were male and, compared with population controls, PD cases were 
more likely to have a positive family history of PD and smoke less. Ninety-four percent of PD 
cases and 97% of controls were ever coffee consumers. 
Heavy coffee drinking in PASIDA is associated with a 25% lower risk of PD 
(OR=0.75[0.64-0.88]), and each additional cup of coffee consumed per day on average is 
associated with a 4% lower PD risk (OR=0.96[0.93-0.99]) (Table 2-S1); inverse coffee-PD 
associations are estimated for both prevalent and incident PD. Of note, the per-cup measure of 
daily coffee consumption was not associated with PD among incident cases. Odds ratio estimates 
adjusted solely for birth year, sex and onset/index age did not substantially differ from estimates 
further adjusted for ever smoking and PD family history. Finally, marginal associations of 
ADORA2A rs5760423 as well as of CYP1A2 rs762551 and rs2472304 (in LD with rs762551: 
r
2
=0.87, D’=0.99) with PD status (incident and prevalent) were null (Table 2-S2).  
Interaction analyses based on all subjects, did not show statistically significantly varying 
effects of caffeine across genotypes of ADORA2A or CYP1A2 polymorphisms, respectively 
(Table 2-2). However, there appeared to be a trend in coffee-PD effect estimates across 
ADORA2A rs5760423 genotypes: The OR for PD among heavy coffee drinkers, relative to light 
coffee drinkers, was 0.81 (0.62-1.05) for GG carriers compared with 0.68 (0.55-0.86) for GT and 
0.54 (0.37-0.78) for TT carriers (OR interaction=0.85 [0.68-1.06], p for interaction =0.14). 
Further adjustment for smoking and PD family history did not change results (data not shown). 
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When we restricted our analyses to incident PD only, we observed a statistically significant 
interaction for the ADORA2A rs5760423 and heavy coffee drinking (OR interaction=0.66 (0.46-
0.94), p for interaction=0.02): the OR for drinking coffee in GG carriers was 1.10 (0.72-1.68), 
0.63 (0.44-0.92) for GT, and 0.58 (0.30-1.09) for TT carriers. When duration of caffeine intake 
was removed from the caffeine measure, the interaction of ADORA2A polymorphism and coffee 
was not statistically significant (p for interaction=0.28 in cup/day for all cases, and p=0.55 for 
incident cases, respectively). There was no evidence for association measure modification for 
CYP1A2 rs762551 and rs2472304 (p for interaction=0.45 and 0.93 respectively). Similarly, 
restricting to incident cases only did not reveal statistically significant interactions for CYP1A2 
SNPs. No interactions were found in prevalent case analyses. Results of interaction analyses 
using other coffee measures, daily intake of caffeine and years of coffee drinking are presented 
in Table 2-S3. We did not observe evidence for effect-measure modification with these measures 
and the SNPs we investigated. 
Our meta-analytic results for coffee-PD associations did not differ much when we used 
random-effects versus fixed-effects models (Table 2-3 and Table 2-S4). Based on random 
effects models, the ADORA2A gene polymorphisms and daily coffee consumption association for 
PD was strongest among rs5760423 TT carriers, OR=0.77 (0.51-1.16), compared with GT and 
GG carriers (OR=0.96 [0.90-1.02] and 0.97 [0.91-1.03], respectively). We saw similar patterns 
for CYP1A2 polymorphisms in both rs762551 and rs24702304, i.e. the coffee-PD associations 
were strongest among homozygotes for the variant alleles (OR=0.86 [0.69-1.08] for rs762551 
CC carriers and 0.84 [0.71-0.99] for rs24702304 GG carriers, Figure 2-1).  
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2.4 Discussion 
We conducted analyses of gene-environment interactions in a Danish case-control study 
of PD. Our study follows up on the results from a previous consortium study (PEGASUS) with 
an equally large sample size. When we include both prevalent and incident PD cases in our 
analysis, we found no evidence for interactions with ADORA2A/ CYP1A2 polymorphisms. 
However when we restricted analyses to incident cases only, we observed interactions between 
the ADORA2A polymorphism and coffee drinking. This difference in results suggests that 
survival or recall bias may affect studies that rely on or include prevalent PD cases. Moreover, 
when we combined our results for incident cases with the PEGASUS incident cases of European 
ancestry in a meta-analytical approach, both ADORA2A and CYP1A2 polymorphisms modified 
coffee-PD associations, although the CYP1A2 interaction was solely due to the influence of the 
PEGASUS study. 
Our PASIDA findings are mostly consistent with those published by the PEGASUS 
consortium which previously reported ORs for PD risk of each additional cup of coffee 
consumed per day among coffee drinkers as 0.93 (0.84-1.03) and 0.92 (0.81-1.04) for CC or CT 
carriers of ADORA2A rs5751876, respectively, and 0.61 (0.46-0.81) for TT carriers ( interaction 
p-value 0.01) in non-Hispanic Whites (Popat et al. 2011). Yet, two smaller studies did not find 
statistically significant interactions for ADORA2A polymorphisms and coffee in PD (Tan et al. 
2006; Facheris et al. 2008). One study was conducted in a mixed-race population that did not 
find the expected inverse main effect for coffee consumption on PD, possibly because sibling 
controls were used (Facheris et al. 2008). Sibling controls are likely too similar to cases in terms 
of coffee consumption, making it hard to estimate effects of coffee consumption on PD risk. The 
second null result was reported for an Asian population with a low average coffee consumption  
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(2.9 in cases vs. 4.7 in controls (Tan et al. 2006) cup-years compared with 161.3 vs. 186.5 cup-
years in PASIDA), such that the exposure levels and contrasts were likely insufficient.  
Animal studies have shown that administration of caffeine or other adenosine A2A 
receptor antagonists before dosing the animal with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) reduces loss of dopamine and dopaminergic neurons, suggesting that 
caffeine reduces PD risk by deactivating the A2A receptors (Chen et al. 2001; Pierri et al. 2005). 
Also, the ADORA2A rs3032740 variant (in LD with rs5751876) has been shown to reduce 
protein expression (Alsene et al. 2003), and thus may result in reduced A2A receptor function that  
together with further inhibition through coffee consumption may exert protective effects (Popat 
et al. 2011). We would thus expect the inverse coffee-PD association to be strongest in those 
with a TT genotype in ADORA2A rs5760423 (in LD with rs5751876). Adenosine A2A receptors 
have also become the latest target for non-dopaminergic therapies in PD based on their 
interaction with dopamine D2 receptors in striatopallidal neurons (Franco et al. 2000; Ferre et al. 
2008).  
Cytochrome P450 1A2 is the main caffeine-metabolizing enzyme that converts over 90% 
of caffeine in the liver to paraxanthine, and its activity depends on age, gender, smoking, and 
CYP1A2 polymorphisms (Sachse et al. 1999; Backman et al. 2008; Gunes et al. 2008). Thus, we 
would expect neuroprotection due to caffeine to be stronger in slow metabolizers who carry the 
variant alleles we investigated. The PEGASUS consortium pooling incident case control studies 
(n=3,060), found evidence for coffee-CYP1A2 interactions with inverse PD associations for 
coffee drinking being strongest in CC genotype carriers at rs762551 and GG genotype carriers at 
rs2472304 (Popat et al. 2011). The NeuroGenetic Research Consortium (n=2,389) did not find 
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interactions with CYP1A2 but included prevalent cases and some studies used spousal controls 
(Hill-Burns et al. 2011). 
Previously, concerns were raised that confounding by population structure in PEGASUS 
produced spurious results (Hill-Burns et al. 2011; Mellick et al. 2011) since allele frequencies for 
CYP1A2 SNPs vary strongly across ethnicities and in PEGASUS the coffee- CYP1A2 
interactions did not reach statistical significance in non-Hispanic Whites alone (Popat et al. 
2011). However, combining PEGASUS and PASIDA non-Hispanic Whites our meta-analysis 
produced a decreasing trend across CYP1A2 rs762551 genotypes (lavender line, Figure 1b) and 
suggested an interaction with cups per day of consumption. Interestingly, ever (vs never) coffee 
consumption produced an inverted-U shape for the CYP1A2 rs762551 polymorphisms, but ever 
(vs never) coffee consumption is a poor measure of average caffeine intake (Table 3).  
Smoking is positively associated with coffee drinking and negatively with PD risk, which 
we have previously interpreted as a consequence of pre-motor prodromal PD (Hernan et al. 
2002). Moreover, a study reported that the metabolic activity did not differ between AC or CC 
and AA carriers at rs762551in non-smokers suggesting that CYP1A2 genotypes may influence 
enzyme activity only in smokers (Sachse et al. 1999). In our study, adjustment for smoking did 
not change the interaction estimates for either of the CYP1A2 SNPs. Complicating the matter 
further, both caffeine and its CYP1A2 metabolite paraxanthine may non-selectively bind to 
adenosine receptor and act as a neuroprotector diminishing somewhat the potential importance of 
CYP1A2 enzyme activity (Xu et al. 2010). The average Danish study participants drank as much 
as 4 cups per day over 40 years implying that levels of caffeine and its metabolites might be 
chronically higher than in other populations consuming less coffee possibly rendering the 
contributions of the metabolizing enzyme less important.  
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Our study has several strengths. We have a large sample size with a homogenous 
ancestry; we selected population controls from Danish registers, assessed confounding (including 
smoking) extensively, and were able to distinguish between incident and prevalent cases. High 
coffee consumption in Denmark allowed us to assess dose-response relationships for coffee and 
PD with great statistical power and since we collected detailed information on lifetime coffee 
consumption we were able to define exposures in various ways. 
Limitations are that very few (<10%) participants reported not drinking coffee such that 
CYP1A2 enzyme activity may not affect caffeine levels in the blood more than minimally 
making it hard to assess the influence of CYP1A2 polymorphisms.  PD prevalent cases tend to 
have more memory loss, therefore lifetime coffee consumption could be misreported or reflect 
changes in drinking habits after diagnosis such as due to sleep problems common in PD patients. 
Also, recall might also be impaired in all cases and controls as the population was on average 68 
years of age at the time of interview, which might be causing non-differential exposure 
misclassification.   
In conclusion, our study corroborates previous findings that interactions between 
ADORA2A rs5760423, CYP1A2 rs762551 and rs2472304 variants and coffee consumption affect 
PD risk. However, since our study only found interaction between ADORA2A rs5760423 and 
coffee for a measure of ‘total cup-years of coffee consumed’ but not ‘average number of coffee 
cups per day’, a measure used in the previous study, we cannot exclude the possibility that 
reverse causation contributed to these results. The lack of a cup-per-day association may, 
however, also be explained by the generally very high coffee consumption levels among Danes, 
i.e. that few Danes consumed so little coffee that each additional cup would make a difference 
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(Popat et al. 2011) Therefore, additional data and studies are still needed in support of the 
hypothesis that a biological effect of caffeine protects against PD. 
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2.5 Tables and Figures 
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Figure 2-1. Odds ratios for cups of coffee consumed per day and PD across ADORA2A / CYP1A2 gene polymorphisms 
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3. Pooled analysis of the interaction between HLA-DRB1 and smoking in Parkinson’s 
disease 
 
3.1 Introduction 
The human leukocyte antigen (HLA) system that encodes the major histocompatibility 
complex (MHC) proteins is a crucial part of the immune system. Class II MHC presents 
extracellular antigens to T lymphocytes. HLA-DR is a MHC class II cell surface receptor 
encoded by the human leukocyte antigen complex on chromosome 6p21.31 and is composed of 
an alpha and beta chain coded by the HLA-DRA and HLA-DRB genes, respectively. While the 
HLA-DRA locus is largely monomorphic and not prominent in HLA-disease association studies, 
the HLA-DRB locus has been reported to influence both autoimmune (e.g., rheumatoid 
arthritis,(Bowes et al. 2008; Bang et al. 2010) multiple sclerosis(Lincoln et al. 2005; Ockinger et 
al. 2016)) and neurodegenerative diseases (e.g., Alzheimer’s disease,(Lambert et al. 2013) 
Parkinson’s disease (PD)(Hamza et al. 2010; Saiki et al. 2010; Do et al. 2011; Ahmed et al. 
2012; Sun et al. 2012)). 
In our previous study, we examined 51 single nucleotide polymorphisms (SNPs) in the 
HLA-DR region in two French case-control datasets. We found that rs660895-G (in the HLA-
DRB1 region) showed the strongest association with PD (OR=0.70, 95% CI=0.57-0.87) and did 
not confirm the previously reported association with the HLA-DRA locus.(Hamza et al. 2010) In 
the same study, SNP-based imputation of HLA alleles showed an inverse association with the 
HLA-DRB1*04 allele,(Ahmed et al. 2012) and this SNP was also the strongest HLA region hit in 
a genome-wide association study.(Do et al. 2011) This finding was corroborated in a British 
case-control study that reported a lower frequency of the HLA-DRB1*04 allele in PD patients 
than in matched controls.(Saiki et al. 2010) A Chinese study also found a reduced risk of PD 
associated with the HLA-DRB1*0406 allele.(Sun et al. 2012) Finally, based on SNP-based 
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imputation of HLA alleles, two GWAS showed an inverse association between 
HLA*DRB1*0404 and PD.(Wissemann et al. 2013)  
PD is likely to be caused by a combination of genetic and environmental factors, acting in 
concert with each other. While smoking increases the risk of many diseases, in particular through 
inflammatory mechanisms,(Walser et al. 2008; Baka et al. 2009) it has consistently been shown 
to be inversely associated with PD.(Ritz et al. 2007) It remains unknown, however, whether this 
robust inverse association is causal or not. Some have argued that it cannot be explained by 
survival bias or confounding,(Morens et al. 1995) but reverse causation cannot be discarded as 
an alternative explanation, due to increasing evidence of a long premotor period.(Ritz et al. 2014; 
Elbaz 2016)  
The identification of gene-environment interactions represents a possible approach to 
better understand the biological mechanisms underlying the association between environmental 
exposures and disease and to improve causal inference. In our previous study we showed that the 
rs660895-PD association was restricted to never smokers (OR=0.63, 95% CI= 0.49-0.81) while 
there was no significant association in ever smokers (OR=0.93, 95% CI=0.61-1.37); however, 
the interaction test was not significant at the traditional α-level of 0.05 (p=0.11),(Ahmed et al. 
2012) and larger studies are necessary to investigate this interaction. 
Thus, the aims of this study were: (i) to investigate the interaction of rs660895 in the HLA-
DRB1 region and smoking in PD in a large population-based case-control study conducted in 
Denmark; (ii) to perform a pooled analysis of the smoking-rs660895 interaction based on 
individual data from the Danish and aforementioned French datasets. 
 
3.2 Materials and Methods  
 
Study population 
31 
 
The data used for analyses have been assembled in the Parkinson’s disease in Denmark 
(PASIDA) study, and the French Terre and Partage studies.  
The PASIDA study: enrolled idiopathic PD patients treated at 10 neurological treatment 
centers and identified from the Danish National Hospital Register between 1996 and 2009. 
Population controls were selected from the Danish Central Population Registry and matched on 
year of birth, sex, and being alive and free of PD at the time of case identification. Detailed 
recruitment information was published previously.(Kenborg et al. 2015) Briefly, from 2,762 
eligible patients, 949 (34%) were excluded due to the following reasons: lack of a PD diagnosis 
on medical records (n=179), declined to participate (n=497), failure to confirm idiopathic PD 
according to accepted criteria in medical record review (n=273).(Wermuth et al. 2012) From 
3,626 eligible controls, 1,887 (52%) completed an interview and questionnaire. Of these, DNA 
samples were available for 1,575 (87%) patients and 1,607 (85%) controls. Later, 20 subjects 
with dementia prior to interview and 20 subjects with missing information for either rs660895, 
ever smoking, or covariates were excluded. Overall, 1547 PD cases and 1595 controls were 
retained in the analysis. 
Terre and Partage studies: Two population-based case-control studies were performed 
within a French health insurance system for persons working in agriculture and related 
occupations (Mutualité Sociale Agricole, MSA). PD patients from 62 metropolitan districts who 
received treatment between 1998 and 1999 were enrolled in the Terre study, whereas those from 
five districts treated between 2006 and 2007 were enrolled in Partage. These patients were 
examined by neurologists and PD was diagnosed using standard criteria.(Bower et al. 1999) We 
randomly selected eligible controls from among all MSA members who requested 
reimbursement for health expenses (Terre) or who were listed on electronic insurance records 
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(Partage). Controls were matched to cases on age, sex, and district of residency, and did not 
report cardinal signs of PD. Subjects with dementia or those who were bedridden were excluded. 
Participation rates were high and similar in cases and controls in both studies (Terre: cases, 83%, 
controls, 75%; Partage: cases, 82%, controls, 77%).(Elbaz et al. 2009; Ahmed et al. 2014) We 
further excluded subjects lacking DNA samples, of non-European ancestry or with missing data, 
leaving 202 PD and 529 controls (Terre) and 307 PD and 599 controls (Partage) for 
analysis.(Levecque et al. 2003; Galanaud et al. 2005) 
The institutional review boards (IRB) of UCLA, the Danish Data Protection Agency, and 
the ethics committee of Copenhagen approved the PASIDA study, whereas the IRB of the 
ethnics committees of the Kremlin-Bicêtre and Pitié-Salpêtrière University Hospitals approved 
the Terre and Partage studies. All subjects provided written informed consent. 
Data collection and smoking assessment  
Participants provided information on demographics and lifestyle through telephone 
interviews or in writing (PASIDA) and in-person interviews (Terre, Partage). In PASIDA, we 
defined ever (habitual) smokers as persons who smoked at least one cigarette, pipe, or 
cigar/cheroot per week for at least 6 months. In the French studies, ever smokers included ex- 
and current smokers of cigarettes who had smoked at least one cigarette per week for at least 6 
months; there were few pipe or cigar/cheroot smokers and all reported smoking cigarettes too. 
For all studies, we collected lifetime smoking information, i.e., the amount and duration of 
smoking and changes of smoking behavior, and used this information to calculate total pack-
years of cigarette smoking. Only smoking behavior that occurred prior to the date of the first 
motor symptom or PD diagnosis in cases and the same index date in matched controls were 
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considered. Information on coffee drinking was available in the PASIDA and Partage studies 
only.(Ahmed et al. 2014) 
Genotyping  
DNA was extracted from saliva (PASIDA, Partage) or blood (Terre) samples. PASIDA 
samples were genotyped for rs660895 using multiplex Taqman allelic discrimination assays 
(Applied Biosystems) according to the manufacturer’s protocol. For Terre and Partage samples, 
rs660895 was included in a microarray that was processed by Integragen (Evry, France) using 
Illumina technology and Infinium iSelect custom genotyping.(Ahmed et al. 2012) All three 
datasets passed the criteria for quality assurance, i.e., genotyping efficiency >95% and accuracy 
>99.5%. 
Statistical analysis 
We assessed Hardy-Weinberg equilibrium in controls from each study using Pearson’s 
chi-square test. For each study, we broke the matching and used unconditional logistic regression 
analysis adjusted for the matching factors (PASIDA: year of birth, sex, onset/index age (age at 
index date); Terre, Partage: index age, sex, and district of residency) to increase statistical 
efficiency. We first assessed the marginal associations of rs660895 and ever smoking with PD, 
and computed odds ratios (OR) and 95% confidence intervals (CI). We also considered family 
history of PD as a potential confounder. Similar to what has been previously reported in the 
literature, we analyzed rs660895 using co-dominant, additive, and dominant genetic models; 
recessive models were not considered due to the low frequency of homozygotes for the minor 
allele. We then examined the independent and joint effects of ever smoking and rs660895 in each 
study. In further analyses, we used pack-years of smoking defined as a three level variable (never 
smoker, ≤18, >18(Levecque et al. 2003)). The 18 pack-years cutoff was the median among not-
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PD affected ever smokers in the Terre study, for PASIDA and Partage, the median pack-years 
among not-PD affected ever smokers was 15 and 12, respectively; we chose the cutoff of 18 to 
separate ligh/moderate from heaviest smokers. We also conducted a sensitivity analysis using 12 
pack-years as the cut-off. Multiplicative interactions between ever smoking and rs660895 were 
examined by introducing a product term between these variables into the regression model. 
Interactions were tested on a multiplicative scale, as departure from multiplicativity is expected 
when at least one of the interacting factors is preventive.(Weinberg 1986) 
Both for analyses of marginal associations and interactions, we pooled the estimates from 
the three studies using random-effects meta-analysis.(Bradburn et al. 1999) We tested for 
between-study heterogeneity with the chi square–based Q statistic (deemed significant for p<.10) 
and quantified its extent with I², which ranges from 0% to 100% and represents the proportion of 
between-study variability ascribed to heterogeneity rather than to chance;(Higgins et al. 2002; 
Higgins et al. 2003) I² values of 0%-24% suggest little heterogeneity, 25%-49% reflect moderate 
heterogeneity, 50%-74% reflect large heterogeneity, and >75% reflect very large heterogeneity. 
Lastly, we assessed the association between rs660895 and smoking among cases and 
controls separately using unconditional logistic regression adjusted for onset/index age, sex, and 
matching factors in each study, and again pooled the three estimates using random-effects meta-
analysis. Case-only studies have been shown to be statistically more powerful than case-control 
studies when assessing gene-environment interactions assuming that the gene-environment 
independence assumption holds, i.e., that rs660895 is not associated with smoking among 
controls.(Khoury et al. 1996) 
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In sensitivity analyses, we checked whether there was an interaction between rs660895 
and coffee drinking and whether adjusting for coffee drinking modified our results for the 
rs660895-smoking interaction. 
All analyses were performed using SAS v9.4 (SAS Institute, Cary, NC, USA) and STATA 
v14.1 (Stata Corporation, College Station, TX, USA). 
Power calculation 
Assuming the following parameters based on 1000 Genomes Project European ancestry 
samples  and the literature (minor allele frequency, MAF: 28%; ever smoking: 70%; marginal 
genetic OR: 0.70;(Ahmed et al. 2012) marginal smoking OR: 0.64;(Noyce et al. 2012) 
ncases = 2,056, ncontrols = 2,723), our study had a statistical power of 97.3% to detect an interaction 
OR of 1.5 (as we previously reported(Ahmed et al. 2012)) at a 0.05 two-sided alpha level under 
an additive genetic model; power was 90.0% for an interaction OR of 1.4. For the case-only 
design, our study had 99.9% statistical power to detect an interaction OR of 1.5 and 98.9% for an 
interaction OR of 1.4. Power calculations were performed in Quanto v.1.2.4 (USC, Los Angeles, 
CA, USA.(Gauderman 2002)  
 
3.3 Results 
The three studies included a total of 2,056 cases (PASIDA, 1,547; Terre, 202; Partage, 
307) and 2,723 controls (PASIDA, 1,595; Terre, 529; Partage, 599) for analysis (Table 3-1). 
There was no deviation from Hardy-Weinberg equilibrium for rs660895 in controls in any 
dataset (PASIDA, p=0.24; Terre, p=0.98; Partage, p=0.31). As expected, compared with control 
subjects, PD patients were more likely to be male, to report a positive family history of PD, and 
to have never smoked (Table 3-1). Table S3-1 shows the cross tabulation of smoking and 
rs660895 in cases and controls from each study. 
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In each study and in the pooled analysis, ever-smoking was inversely associated with PD 
(pooled OR=0.56, 95%CI: 0.49-0.64, p<0.001; Table 3-2) with a dose-effect relation (p for trend 
<0.001) and without any heterogeneity across studies (I²=0.0%). Similar to what we reported 
previously(Ahmed et al. 2012), we observed an inverse association between rs660895-G and PD 
in the Danish study (OR per one-minor allele=0.85, 95% CI=0.75-0.96, p=0.010). In the French 
studies, OR estimates adjusted solely for onset/index age and sex did not differ from estimates 
further adjusted for district of residency, thus only data from the former analysis are shown. The 
inverse association between rs660895-G and PD was significant in pooled analyses (OR per one-
minor allele=0.79, 95% CI=0.68-0.93, p=0.003) with moderate heterogeneity (I²=31.3%) and no 
heterogeneity under a dominant model (OR=0.79, 95% CI=0.70-0.90, p<0.001, I²=0.0%). 
Table S3-2 shows analyses of the interaction between smoking and rs660895 in each 
study and Table 3-3 shows results of the pooled analysis. In PASIDA, the interaction between 
ever smoking and rs660895 was statistically significant, no matter which genetic model was 
considered. Under the dominant model, the inverse association between rs660895-G carriers and 
PD in never smokers (OR=0.66, 95% CI=0.53-0.82) was lost in ever smokers 
(OR=0.46/0.46=1.00, 95% CI=0.82-1.21) corresponding to an interaction OR of 1.52 (95% 
CI=1.13-2.04, p=0.005); the inverse association between smoking and PD seen in rs660895-G 
non-carriers (OR=0.46, 95% CI=0.38-0.56) was weaker in rs660895-G carriers 
(OR=0.46/0.66=0.70, 95% CI=0.54-0.86). Interactions ORs were of a similar size, but not 
statistically significant, in the French studies (Terre, OR=1.74, 95% CI=0.79-3.84, p=0.17; 
Partage, OR=1.52, 95% CI=0.76-3.06, p=0.24). In pooled analyses of the three studies (Table 3-
3), there was no heterogeneity for any of the interaction estimates. Under a dominant model, 
rs660895-AG+GG was inversely associated with PD among never smokers (OR=0.64, 95% 
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CI=0.54-0.77) but not in ever smokers (OR=0.48/0.48=1.00, 95% CI=0.84-1.19), corresponding 
to an interaction OR of 1.54 (95% CI=1.19-2.00, p=0.001, I²=0.0%); similarly, the inverse 
association between smoking and PD seen in rs660895-G non-carriers (OR=0.48, 95% CI=0.41-
0.57) was weaker in rs660895-G carriers (OR=0.48/0.64=0.75, 95% CI=0.60-0.90). In analyses 
based on pack-years, interactions were significant for both light (OR=1.64, 95% CI=1.20-2.25, 
p=0.002) and heavy (OR=1.48, 95% CI=1.02-2.13, p=0.040) smoking; interaction ORs were 
somewhat stronger for light than heavy smoking but the difference was not significant (p=0.68). 
Results remained consistent when the cutoff of 12 pack-years was used (light smokers: OR 
interaction=1.71, 95% CI=1.22-2.41, p=0.002; heavy smokers: OR interaction=1.47, 95% 
CI=1.06-2.05, p=0.021). 
Table 3-4 presents the results of case-only and control-only analyses. Case-only analyses 
showed a significant and positive association between ever smoking and rs660895-G in cases 
from PASIDA under all genetic models considered. This pattern was confirmed in pooled 
analyses without any heterogeneity across studies (I²=0.0% for all genetic models). Among 
controls, rs660895-G tended to be less frequent among ever smokers than never smokers, but this 
difference was not significant in any of the studies and in pooled analyses. 
Both in the PASIDA and Partage studies, smoking and coffee drinking were positively 
associated in controls. There was no significant interaction between rs660895 and coffee 
drinking (either as a binary variable or in cups per day) in both datasets and in pooled analyses; 
in addition, the rs660895-smoking interaction remained significant in PASIDA and in pooled 
analyses after adjusting for coffee consumption (data not shown). 
 
3.4 Discussion 
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In this pooled analysis of individual data from three population-based case-control studies, 
we replicate an inverse association between rs660895-G and PD, and provide the first evidence 
of a statistically significant interaction between rs660895 and smoking for the risk of PD. The 
inverse association between rs660895-G and PD significantly decreased in smokers compared to 
non-smokers. 
We previously reported significant associations of the HLA-DRB1*04 allele and rs660895 
with PD, and a strong correlation of rs660895-G with HLA-DRB1*04 (Spearman’s rho= 0.77, 
p<0.0001) in the French studies included here.(Ahmed et al. 2012) These results are in 
agreement with our findings for rs660895 in the Danish study. Additionally, a British study of 
528 cases and ~3000 controls previously reported a lower HLA-DRB1*04 allele frequency in PD 
patients compared with controls (17% vs. 20%, p=0.01). A subtype of HLA-DRB1*04, HLA-
DRB1*0406, which is rare in European but common in Asian populations, was also significantly 
related to PD in a Han Chinese study of 567 cases and 746 controls (OR=0.12, p=5x10
-5
).(Sun et 
al. 2012) An inverse association between HLA*DRB1*0404 and PD was also reported in two 
GWAS using SNP-based imputation.(Wissemann et al. 2013) These findings support a role of 
HLA-DRB1 in the etiology of PD across ethnicities. The HLA-DRB1 gene encodes MHC class II 
beta chain proteins, which are widely expressed on antigen presenting cells such as B cells, 
dendritic cells, and macrophages, including brain microglia. Studies have reported microglial 
activation in the substantia nigra of PD patients and in animal models, and some suggested that 
modulation of microglia related oxidative stress and inflammation might be a treatment strategy 
for PD.(McGeer et al. 1988; McGeer et al. 2008) Observational studies showing an inverse 
association between NSAIDs use and PD also support a role for neuroinflammation in 
PD.(Gagne et al. 2010) 
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In addition, our findings suggest that the inverse association between HLA*DRB1 and PD 
is present only in never smokers, and the smoking-PD inverse association was less pronounced 
in rs660895-G carriers. In analyses based on pack-years of smoking, although interaction ORs 
tended to be higher for light smokers than heavy smokers, the difference was small and not 
statistically significant. The finding that interaction effects on an endpoint decrease with 
exposure has previously been termed ‘low exposure – gene effect’ with several examples 
available in the cancer literature(Taioli et al. 1998); i.e. the interaction is relevant for the 
outcome at low doses while at high doses the interaction does not matter. Even larger studies 
would be needed to further investigate such dose dependent patterns for smoking and HLA-
DRB1 in PD.  
Epidemiologic studies have consistently reported a significant inverse association between 
smoking and PD with a dose-effect relation.(Ritz et al. 2007) This has led some researchers to 
advocate the use of nicotine to prevent or treat PD.(Quik et al. 2012) There is however no 
consensus yet whether this association is causal or is due to bias or reverse causation, such that 
those who will develop PD have a diminished nicotinic response allowing them to quit more 
easily in the prodromal phase of PD; indeed, in PASIDA, the risk of developing PD was higher 
among former smokers who reported that quitting had been easy and who did not use nicotine 
substitutes.(Ritz et al. 2014) Gene-environment studies may represent a way to improve our 
understanding of the mechanisms underlying the puzzling association between smoking and PD. 
Our finding of a sub-multiplicative interaction between HLA-DRB1 and smoking suggests that 
they are involved in common pathways, possibly related to neuroinflammation; further research 
is needed to better understand the mechanism underlying the HLA-DRB1-PD association and the 
interaction with smoking. In this context, it is of interest that smoking and HLA have been 
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previously reported to interact in other conditions, including multiple sclerosis (MS),(Simon et 
al. 2010; Ockinger et al. 2016) rheumatoid arthritis (RA),(Bang et al. 2010; Karlson et al. 2010; 
Bang et al. 2013) lymphoma,(Baecklund et al. 2017) and adult idiopathic inflammatory 
myopathies.(Chinoy et al. 2012) In MS patients, smoking influenced the proliferation of immune 
cells in the lung; the magnitude of the increase in alveolar macrophage concentration was 
associated with HLA-DRB1 alleles.(Ockinger et al. 2016) In RA sufferers, smoking and HLA-
DRB1*04 interacted to influence their risk of cardiovascular disease;(Boechat Nde et al. 2012) 
the hypothesized mechanism was that both HLA-DRB1*04 and smoking enhanced T-cell 
activation in the lung, which may lead to inflammatory processes in the endothelial cells of the 
vessel walls and subsequent development of cardiovascular disease. Regarding lymphoma, a 
recent study showed a positive association with HLA-DRB1 shared epitope alleles (including 
HLA-DRB1*04) as well as a positive additive interaction between HLA-DRB1 shared epitope 
alleles and smoking, such that there was no association with smoking in subjects without shared 
epitope alleles and a significant positive association in those who carried two shared epitope 
alleles.(Baecklund et al. 2017) Smoking induces the release of intracellular antigens and the 
authors hypothesized that shared epitope-containing HLA-DRB1 variants may facilitate the 
presentation of these antigens to helper T cells and induce B-cell chronic activation which may 
increase the risk of abnormal proliferation.(Baecklund et al. 2017) Interestingly, a meta-analysis 
showed PD patients to have a 24% reduced risk of leukemia and lymphoma.(Bajaj et al. 2010) 
This finding is in agreement with associations in opposite directions for HLA-DRB1 with PD and 
lymphoma; although it is unclear how smoking and HLA-DRB1 may interact at the biological 
level, the observation of interactions in opposite directions in both diseases, one characterized by 
cell proliferation and the other by neuronal death, deserves further investigation. Lastly, smoking 
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and HLA-DRB1 have also been reported to interact in adult idiopathic inflammatory 
myopathies.(Chinoy et al. 2012) 
Our study has several strengths including its large size and study design (pooled analysis 
of individual data from three population-based studies) that provided us with sufficient statistical 
power to identify an interaction of the size previously reported(Ahmed et al. 2012) or even 
weaker. In case-only analyses, rs660895 was associated with smoking among cases and the 
assumption of gene-environment independence among controls was met. As studies were 
population-based, controls were representative of the underlying population from which the 
cases arose. In addition, in each study, participants were ethnically homogeneous and of 
European ancestry. The diagnosis of PD was clinically confirmed by neurologists in the two 
French studies, and by careful systematic review of complete medical records in PASIDA. 
Finally, the effect size of ever smoking was consistent with that reported in a previous meta-
analysis of 67 studies (OR=0.64, 95% CI=0.60-0.69).(Noyce et al. 2012) However, there are also 
limitations. Although rs660895-G tags the HLA-DRB1*04 allele, we cannot provide more 
detailed information about allele subtypes and haplotypes as additional SNPs were not typed.  
Besides, the recruitment of PD patients includes both incident and prevalent cases, but stratifying 
by disease duration produced the same results making survival bias unlikely (data not shown). 
Finally, residual confounding due to unmeasured factors cannot be ruled out; however, under 
gene-environment independence in the population, it has been shown that only unmeasured 
confounders that also interact with the gene under investigation may bias estimates of gene-
environment interactions.(Vanderweele et al. 2013) In our analyses, coffee did not interact with 
rs660895-G for the risk of PD, and adjusting for coffee drinking had no impact on our findings. 
In our previous paper, we also reported that there was no interaction between HLA-DRB1 and 
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professional pesticide exposure in the French dataset (p for interaction=0.88).(Ahmed et al. 
2012)  
In conclusion, our findings suggest that genetic variation in the HLA-DRB1 locus has an 
effect on the risk of Parkinson’s disease in interaction with smoking, and that the protective 
effect of the G allele of HLA-DRB1 rs660895 in PD is present only in never smokers. Our study 
further emphasizes the importance of neuroinflammation in the development of PD. 
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4. Coffee Consumption is Associated with DNA Methylation Levels of Human Blood 
4.1 Introduction 
Coffee is one of the most widely consumed beverages in the world and is believed to 
have potential health risks and benefits(Butt et al. 2011). Coffee consumption has been linked 
to a wide range of health outcomes including cardiovascular, metabolic, and neurocognitive 
function. Heavy coffee consumption induces cardiovascular  responses and insomnia(Butt et 
al. 2011), but coffee consumption has also been associated with lower risk of type 2 diabetes, 
endometrial cancer(Giri et al. 2011), and neurodegenerative diseases such as Parkinson’s 
disease (PD) and Alzheimer’s disease (AD)(Qi et al. 2014).  Caffeine is thought to prevent 
cognitive decline by inhibiting formation of beta-amyloid and by acting as an anti-
inflammatory agent in AD(Chen et al. 2001; Arendash et al. 2006), whereas in PD, it is 
thought to reduce neuroinflammation and lipid-mediated oxidative stress(Farooqui et al. 2011; 
Ferrari et al. 2011). AD and PD are slowly progressive diseases with a long prodromal phase, 
making it difficult to rule out reverse causality such that at risk individuals may decrease 
coffee intake due to development of sleep problems or loss of smell(Wirdefeldt et al. 2011). 
            Genomic studies identified eight genetic loci that have an influence on habitual coffee 
consumption, including some near CYP1A2 and AHR, encoding the caffeine metabolizing 
enzyme Cytochrome P450 1A2 and a CYP1A2 regulator Aryl Hydrocarbon Receptor, 
respectively,(Cornelis et al. 2011; Cornelis et al. 2015). DNA methylation (DNAm) might act 
as a potential epigenetic mediator for caffeine’s influence on health(Petronis 2010). 
Mechanistic epigenetic studies of caffeine have mainly focused on animal 
models(Buscariollo et al. 2014; Ping et al. 2014; Wu et al. 2015). For example, maternal 
prenatal caffeine intake increased methylation of the steroidogenic factor-1 promoter in fetal 
adrenal tissue in mice(Ping et al. 2014) whereas caffeine elicited effects similar to acute 
exercise in rat skeletal muscle tissue and resulted in lower DNA methylation levels in 
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promoter regions of energy metabolism genes(Barres et al. 2012). Little is known whether 
epigenetic changes can be found in human due to their coffee consumption habits. Exploring 
whether coffee consumption affects DNA methylation can help identify epigenetic signatures 
and provide mechanistic insights for results from  past epidemiological studies and possibly 
new insights into health risks or benefits of coffee consumption. 
            Here, for the first time we identified DNA methylation sites from a genome-wide 
screen that relate to habitual coffee consumption in humans. We conducted a meta-analysis of 
DNA methylation levels in blood samples from two different data sets: PD-free control 
subjects enrolled in the Parkinson’s Environment and Genes (PEG first round, 2001-
2007(Kang et al. 2005; Narayan et al. 2013)) study consisting of 215 non-Hispanic 
Caucasians, and women from the WHI consisting of 995 Caucasians, 431 Hispanics, and 674 
African Americans. We also related coffee consumption to DNA methylation levels in saliva 
samples from 127 PD patients and 129 PD-free controls (age-, gender-, and ethnicity-
matched) enrolled in the second round of the PEG study (2009-ongoing)(Costello et al. 2009; 
Narayan et al. 2015). Detailed information for each dataset can be found in Table S1 and in 
Methods. 
 
4.2 Materials and Methods  
Description of PEG1 subjects  
            Study population: This dataset consists of 215 Caucasian population controls with 
complete information on coffee consumption and blood samples for DNA. The PEG1 study is 
a population-based case control study in central California (Fresno, Kern, or Tulare Counties) 
recruiting subjects from 2001 to 2007. To be eligible, participants had to be residents of one 
of three central California counties, had to have lived in California for at least 5 years, and to 
be at least 35 years of age(Kang et al. 2005). Population controls were identified from 
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Medicare lists and also using residential property tax assessor records. Potential controls were 
screened for eligibility by mail or telephone, and only 1 person per household was allowed to 
enroll(Costello et al. 2009; Narayan et al. 2015). The study was approved by the UCLA 
Institutional Review Board, and informed consent was obtained from all subjects. 
            Exposure assessment: Standardized interviews were conducted to obtain information 
on demographics, lifetime caffeinated beverage consumption, smoking, and MHT histories. 
In the interview, information on the frequency and amount of caffeinated beverage 
consumption at different periods of lifetime were collected: young adult <25 years, adult 25-
44 years, middle-aged 45-64 years, and senior ≥65y years. We used this information to 
calculate weighted average daily coffee consumption. Only caffeinated coffee consumed 
during the past 12 months prior to the date of blood draw contributed to our exposure 
measures.  
Description of PEG2 subjects  
            Study population: This dataset consists of data from 127 PD patients and 129 
population controls with complete information on coffee consumption and saliva samples we 
extracted DNA from recruited for the PEG2 study which started in 2009 (ongoing). PD 
patients were identified using the California PD Registry for the three target counties in 
central California. Those who lived in the study area were eligible and were mailed 
invitations and those who agreed were examined by a UCLA movement disorder specialist 
who applied UK Brain Bank and Gelb diagnostic criteria(Hughes et al. 1992; Gelb et al. 
1999). Controls selection was based on the same criteria as in the PEG1 study but only used 
tax assessor records to identify residents whom we recruited at the door step. Saliva samples 
selected from PEG2 participants were matched on age, gender, and race for cases and 
controls.                         
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            Exposure assessment: Methods for assessing exposure were identical to the methods 
employed in the PEG1 study. 
            Phenotype data and DNA methylation data of the PEG studies are available at GEO 
accession database GSE72775 (blood) and GSE78874 (saliva). 
WHI subjects Description  
            Study population: This dataset consists of a sub-group of 2,100 women (995 
Caucasians, 431 Hispanics, and 674 African Americans) with complete information on coffee 
consumption as well as genome-wide DNA methylation data from blood drawn at baseline. 
The WHI is a multi-center study launched in 1993 which enrolled post-menopausal women 
aged 50-79 years into either one or more randomized Clinical Trials (RCTs) or an 
observational study(Anonymous 1998). These women were originally selected from two 
WHI subcohorts for a nested genomic case-control study of coronary heart disease (CHD) 
with genome-wide genotype and cardiovascular disease related biomarker data.(Curb et al. 
2003) Thus, fifty percent (n=1,053) of these WHI women were eventually diagnosed with 
CHD; however, disease status has no effect on DNA methylation level measured at baseline. 
The two cohorts are: 1) the WHI SNP Health Association Resource (SHARe) cohort which 
includes genotyping data from ~8500 African American and ~3500 Hispanic women through 
WHI core study M5-SHARe (www.whi.org/researchers/data/WHIStudies/StudySites/M5) as 
well as information on biomarker through WHI Core study W54-SHARe 
(...data/WHIStudies/StudySites/W54); 2) the  two European Americans Hormonal Therapy 
(EA HT) trials selected for GWAS and biomarkers in core studies W58 
(.../data/WHIStudies/StudySites/W58) and W63 (.../data/WHIStudies/StudySites/W63). 
            Exposure assessment: Information on demographics, smoking history, and MHT were 
obtained using a structured questionnaire at baseline. Food frequency questionnaires were 
used to collect information on daily coffee or tea (all types) consumption in the past 3 months 
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prior to baseline. Our exposure measures were directly taken from answers provided in 
response to the questionnaire.  
DNA extraction and Genome-wide DNA methylation analysis  
            DNA methylation data were obtained from the Infinium HumanMethylation450 
BeadChip (Illumina, San Diego, CA) using DNA samples extracted from peripheral blood 
cells and leukocytes in saliva. Methylation beta-values ranging from 0 (unmethylated) to 1 
(fully methylated) were used for analysis.(Dunning et al. 2008)  
Statistical analyses 
            The raw methylation data was preprocessed using the background normalization 
method from the Genome Studio software. To assess correlations between continuous coffee 
consumption (cup/day) and site-specific DNA methylation levels, biweight midcorrelation 
(bicor) was applied in a genome-wide screen. In the main correlation analysis using DNA 
methylation levels from blood, potential confounders such as age at blood draw, gender, and 
blood cell counts were adjusted for by regressing out the effects of these factors and retaining 
the residuals. Smoking status (ever vs. never) was further adjusted for in ancillary analyses. 
We used the Houseman algorithm in the minfi R package and epigenetic clock software for 
estimating blood cell counts(Houseman et al. 2012; Horvath 2013; Jaffe et al. 2014). All 
blood analyses were stratified by ethnicity, thus four subsets were generated: PEG1 
Caucasians PD-free controls, WHI Caucasians, WHI Hispanics, and WHI African Americans. 
In order to obtain an overall p-value across the four subsets, we conducted a meta-analysis 
using Stouffer’s method for combining Z-values (meta.Z) i.e. Σzi/sqrt(4). The corresponding 
two-sided p-values (meta.pvalue) were calculated under the assumption of a normal 
distribution. These approaches were also applied to identify smoking-associated CpGs and 
CpGs influenced by both coffee and smoking. We then identified the top-ranked coffee-
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associated CpGs by meta.pvalue, and applied functional enrichment analysis on 2,124 genes 
identified from the top 3,000 most significant coffee-associated CpGs (meta.pvalue threshold 
~ 1.1x10
-3
) using the online bioinformatics tool – the Database for Annotation, Visualization 
and Integrated Discovery (DAVID v.6.7). We further conducted MHT-stratified meta-
analysis for the top 11 coffee-associated CpGs using the WHI data in order to investigate the 
modifying effect MHT has on the coffee-DNAm association. In the analysis using DNA 
methylation levels from saliva in PEG2, potential confounders such as age at saliva 
collection, gender, and ethnicity were adjusted for as above. Analyses and scatter plots were 
created using the WGCNA package in R v.3.1.2, while Manhattan plots of epigenome-wide 
association study (EWAS) p-values were generated with the qqman package. QQ-plots of 
EWAS pvalues were also generated in R, and lambda i.e. median(chi
2
)/0.454, were calculated 
to identify potential inflation.   
 
4.3 Results and Discussion 
Coffee consumption and DNA methylation levels in blood 
            In our EWAS study, we analyzed methylation levels of approximately 486k CpGs on 
the Illumina 450K array. Since many CpGs exhibit strong pairwise correlations, the 
Bonferroni-corrected significance threshold of α=0.05/500,000=1x10-7 was considered overly 
conservative; we used a modified threshold of p<5x10
-6
 to evaluate genome-wide 
significance in our study. In the PEG1 and WHI datasets, adjusting for chronological age, 
gender, and imputed blood cell counts, we identified one CpG with genome-wide Bonferroni 
corrected significance: cg21566642 near the ALPPL2 gene (meta.p=3.7x10
-10
). Ten 
additional CpGs surpassed the significance threshold of p<5.0x10
-6
 (Table 4-1a and Figure 
4-1a) and are located in/near the genes GPR132, BSCL2, MALRD1, GRK5, PSMD8, FSTL5, 
PTHLH, etc. (Table 4-1a). 
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 The top ranked CpGs appear to be linked to genes involved in lipid metabolism 
(Miranda et al. 2009; Vangaveti et al. 2010; Vergnes et al. 2013; Stringhini et al. 2015) and 
immune response [RefSeq, Jul 2008]. For instance, the protein encoded by GPR132 is a 
receptor for oxidized free fatty acids and is a treatment target for diabetes because of its role 
in lipid metabolism and antioxidant activity(Vangaveti et al. 2010). In a mixed-race study of 
atherosclerosis, GPR132 was found to be hypomethylated among low socioeconomic status 
(SES) individuals with increased inflammatory activity compared with high SES 
individuals(Stringhini et al. 2015). BSCL2 encodes the transmembrane protein “seipin” 
residing in the endoplasmic reticulum. Variants in BSCL2 cause congenital generalized 
lipodystrophy, characterized by the loss of adipose tissue and severe insulin 
resistance(Miranda et al. 2009). MALRD1 encodes yet another lipid-related gene that has 
been shown to regulate bile acid and lipid levels in the enterohepatic system(Vergnes et al. 
2013). Genes related to immune response include GRK5 and PSMD8. The protein encoded 
by GRK5 regulates polymorphonuclear leukocyte motility, while PSMD8 encodes an 
immune-proteasome component related to major histocompatibility (MHC) class I antigen 
processing and presentation [provided by RefSeq, Jul 2008]. These coffee-associated CpGs 
were mostly located within 200 to 1,500 bps upstream of a transcription start site of a gene i.e. 
promoter region (Fisher’s p=0.03, Figure 4-1b). Additional stratified analyses for the PEG 
and WHI samples, as well as comparisons of effect sizes between genders or ethnicities are 
provided in Table 4-S2, 4-S3, and Table 4-1. 
            Many studies have focused on associations between DNA methylation and smoking, 
and it is well known that a subgroup of coffee consumers is more likely to smoke. The 
highest correlation we observed between coffee intake and smoking in any of our cohorts was 
r=0.31 among PEG1 Caucasian controls (p=3.4x10
-6
). Due to the common co-exposure to 
coffee and smoking, any adjustment for smoking is expected to affect associations between 
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DNA methylation and coffee consumption. Indeed, smoking adjustment reduced the 
statistical significance of cg21566642 (meta.p=5.4x10
-4
, Table 4-2 and Figure 4-2a) to less 
than the genome-wide threshold. However, associations between the 11 top-ranked CpGs and 
coffee consumption were still preserved after smoking adjustment (meta.p<0.05/11=4.5x10
-3
, 
Table 4-2). Further, we identified methylation differences for 135 CpGs associated with both 
coffee drinking and smoking (meta.p≤1.0x10-7, Table 4-S4). After smoking adjustment, the 
most significant differentially methylated genes were BSCL2 and GPR132, along with 
CNTN4 and ROBO3 which appear to be involved in axonal navigation. (meta.p ≤5x10-6, 
Table 4-1b). 
            It is worth noting that genetic variants previously linked to coffee consumption in 
GWAS did not reach the significance threshold of p≤1.0x10-3 in our study, specifically AHR, 
CYP1A1, CYP1A2, NRCAM, and ADORA2A(Cornelis et al. 2011; Hamza et al. 2011; Amin et 
al. 2012; Byrne et al. 2012; Cornelis et al. 2015). However, our study corroborated the 
importance of the STK11 gene (cg24145685: meta.Z=4.54, meta.p=5.7x10
-6
; after smoking 
adjustment: meta.Z=3.99 and meta.p=6.6x10
-5
), which encodes a member of the 
serine/threonine kinase family and interacts with another gene (CAB39L) identified in a 
previous GWAS focused on coffee consumption(Amin et al. 2012). 
            As mentioned above, previous studies reported reduced risks of developing PD and 
AD with habitual coffee consumption(Hernan et al. 2002; Barranco Quintana et al. 2007). To 
the best of our knowledge, our blood tissue data did not include AD or PD patients. 
Surprisingly, we found some CpGs located near genes linked with familial forms of PD 
associated with coffee consumption: GBA (meta.p=7.9x10
-5
), PARK2/Parkin (meta.p=7.3x10
-
4
), and PINK1 (meta.p=8.9x10
-4
). Similarly, some GWAS-identified loci for AD were also 
associated with coffee intake: PICALM (meta.p=1.3x10
-5
), CLU (meta.p=6x10
-4
), and EDC3 
(meta.p=1.1x10
-4
)(Harold et al. 2009; Victor Junji Yamamoto 2015). The PARK2 gene 
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encodes an ubiquitin protein ligase called Parkin that targets proteins for degradation in the 
proteasome. Pathways related to Parkin include oxidative stress, Class I MHC antigen 
processing and presentation and alpha-synuclein signaling(Andersen 2004). The EDC3 gene 
is also of interest since it is located near CYP1A1/CYP1A2 and the enzymes  encoded by them 
may interact with coffee consumption in reducing AD risk.(Victor Junji Yamamoto 2015)  
            Using the 2,104 genes linked with the 3,000 most significant coffee-associated CpGs 
(p≤1.1x10-3 without smoking adjustment) in gene set enrichment analysis, we identified 
2,901 CpGs (in/near 2,058 genes) that were hyper-methylated in habitual coffee drinkers, 
while only 3% (99 CpGs in/near 66 genes) were hypo-methylated. Results of the DAVID 
functional analysis showed that these coffee-associated genes are enriched in functional 
categories of transcription factor binding (p=1.2x10
-6
, Table 4-3) and protein kinase activity 
(p=2.9x10
-5
). The enriched biological terms remained statistically significant after correcting 
for multiple comparisons (Benjamini-adjusted p< 0.05).   
            It has previously been suggested that the potential protective action of coffee on PD in 
women may be abrogated by postmenopausal estrogen use (Ascherio et al. 2004; Palacios et 
al. 2012). Interestingly, when we stratified the participants from the WHI by MHT, we 
observed significant associations between coffee consumption and the 11 top CpG sites from 
Table 4-1a only in women who never used MHT and not in MHT users (Table 4-4).  
Coffee consumption and DNA methylation levels in saliva 
            We also evaluated associations between coffee and genome-wide DNA methylation 
levels in saliva provided by 256 participants with and without PD enrolled in the PEG2 study. 
After adjustment for chronologic age, gender and ethnicity, no CpGs achieved genome-wide 
significance (p≤10-7, Figure 4-3a). When examining the 11 most significant coffee-
associated CpGs we previously identified in blood, none of the significant associations were 
preserved in saliva (Table 4-2). Moreover, we did not observe positive correlations between 
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meta-Z values for blood and Z values for saliva (Figure 4-3b). Further adjustment for PD 
status did not change these results (Table 4-2), suggesting that PD status did not affect DNA 
methylation levels in saliva for the coffee-related CpGs identified in blood. After adjusting 
for smoking, there appeared to be a significant correlation for coffee-related DNA 
methylation in blood and in saliva tissues, but in the opposite direction of what we expected 
(Figure 4-4b and Table 4-S5). This can be explained by the ‘regression to the mean’ effect, 
suggesting DNA methylation data from saliva did not replicate associations we found in 
blood.  
Potential limitations 
Our study has some potential limitations: First, we have a small amount of uncertainty 
regarding the reported ethnicity since we do not have genome-wide SNP data to compute the 
genetic principal components. However, ethnicity information in the studies we included 
have been carefully verified using 37 Ancestry Informative Markers (AIM). Moreover, we 
stratified by ethnicity to address the possibility of ethnic confounding. Second, stratification 
by gender in the PEG1 study removed the significance of some of the associations between 
coffee consumption and methylation loci. However, this might be due to the decreased 
sample size imparted by stratification. Third, similar to other DNA methylation studies, 
lambda values in this study were inflated; therefore, we should interpret p-values with caution. 
However, our findings in Caucasians were replicated in other ethnic groups giving some 
validation to the results. In addition, it remains debatable whether to present QQ-plots in 
DNA methylation studies, since CpGs are highly correlated and the distributional 
assumptions made in GWAS may not be met in EWAS (see Figure 4-S1).  
 
4.4 Conclusions 
            In summary, in peripheral blood mononuclear cells we identified CpGs located near 
11 genes that were associated with habitual coffee consumption based on the significance 
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threshold (meta.p≤5.0x10-6) while adjusting for age, gender, and blood cell composition. 
Moreover, these correlations remained significant after further adjustment for smoking. 
Furthermore, many differentially methylated CpGs are located in/near genes reported to be 
associated with coffee-related chronic diseases or the common neurodegenerative diseases 
PD and AD for which coffee consumption has been suggested to be protective. Our results 
point to possible mechanisms through which coffee consumption may have beneficial effects 
and possibly may confer risk reduction. The measures of habitual coffee consumption we 
used in this study were based on recall over a short period (last 3 months in WHI or 12 
months in PEG1); however, in PEG1 reported lifetime coffee consumption was highly 
correlated with coffee consumption reported for the past 12 months (cor=0.87), suggesting 
that coffee consumption is consistent across time. Moreover, this is a mixed-race and mixed-
gender study, therefore the coffee associations with DNA methylation levels in blood appear 
to extend to both genders and different ethnic groups, even though in women, results also 
seemed to depend on MHT use. Lastly, our study suggests that while coffee affects DNA 
methylation levels in blood this does not seem to extend to saliva-derived tissue. 
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4.5 Tables and Figures 
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(a)      
 
 
 
 
(b)      
     
 
 
 
 
 
 
 
 
 
 
Figure 4-1. Blood DNA methylation levels associated with coffee consumption adjusted for 
age, gender and blood cell counts. (a) Manhattan plot of the meta-analysis methylation 
association p-values adjusted for chronological age, gender and blood cell counts. The red line 
indicates p-value threshold of 10
-7
. One CpG on chromosome 2 passed this threshold. The x-axis 
corresponds to negative log10 transformed meta.p-value. The x-axis refers to chromosome 
number, and X and Y chromosomes. (b) Distributions of CpGs relative to CpG island and gene 
regions for all 450k CpGs on the microarray and the 11 most significant coffee-associated CpGs 
listed in Table 4-1a. P-values were obtained by Fisher’s test for comparing proportions.  
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(a) 
  
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2. Blood DNA methylation levels associated with coffee consumption adjusted for 
age, gender, blood cell counts and smoking. (a) Manhattan plot of the meta-analysis 
methylation association p-values adjusted for chronological age, gender, blood cell counts, and 
smoking. Red line indicates p-value threshold of 10
-7
- no CpG passed this threshold. X-axis 
corresponds to negative log10 transformed meta.p-value. Y-axis refers to chromosome number, X 
and Y chromosomes. (b) Distributions of CpGs relative to CpG island and gene regions for all 
450k CpGs on the microarray and the 5 most significant coffee-associated CpGs listed in Table 
4-1b. P-values were obtained by Fisher’s test for comparing proportions.  
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(a) 
 
(b)  
 
 
 
 
 
 
 
 
 
 
Figure 4-3. Saliva DNA methylation levels associated with coffee consumption adjusted for 
age, gender and ethnicity. (a) Manhattan plot of the methylation association p-values adjusted 
for chronological age, gender and ethnicity. Red lines indicate the p-value threshold of 10
-7
-no 
CpGs passed this threshold. the x-axis corresponds to negative log10 transformed meta.p-value. 
the y-axis refers to chromosome number, and X and Y chromosomes. (b) Correlation between Z-
values from biweight midcorrelations between DNA methylation and coffee consumption in 
blood and saliva for 50 most hypermethylated CpGs and 50 most hypomethylated CpGs in blood. 
The x-axis corresponds to the meta Z-values adjusted for age, gender and blood cell counts from 
PEG1 and WHI. The y-axis corresponds to the Z-values adjusted for age, gender and ethnicity 
from PEG2. 
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Figure 4-4. Saliva DNA methylation levels associated with coffee consumption adjusted for 
age, gender, ethnicity and smoking. (a)Manhattan plot of the methylation association p-values 
adjusted for chronological age, gender, ethnicity and smoking. Red line indicates p-value 
threshold of 10
-7
-no CpG passed this threshold. X-axis corresponds to negative log10 transformed 
meta.p-value. Y-axis refers to chromosome number, X and Y chromosomes. (b) Correlation 
between Z-values from bi-weighted midcorrelations between DNA methylation and coffee 
consumption in blood and saliva for 50 most hypermethylated CpGs and 50 most 
hypomethylated CpGs in blood. X-axis corresponds to the meta Z-values adjusted for age, 
gender, blood cell counts and smoking from PEG1 and WHI. Y-axis corresponds to the Z-values 
adjusted for age, gender, ethnicity and smoking from PEG2. 
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4.6 Supplement 
Supplementary Table 4-S1. Characteristics of subjects and exposures  
The rows correspond to the datasets used in this article from three studies stratified by race and PD status.  Columns report tissue types, disease 
status (N, %), mean age at blood draw (and range), number female (%), average of daily coffee/tea consumption (SD), smoking status (N, %), 
and information on MHT use in females (N, %).   
 
Blood samples (N=2,315) 
 
Saliva samples (N=256) 
 
PEG1 Ctrl 
(N=215)  
WHI  
(N=2,100)  
PEG2 PD patients  
(N=127) 
PEG2 Ctrl  
(N=129) 
  Caucasian   Caucasian Hispanic 
African 
American 
  Caucasian Hispanic Caucasian Hispanic 
Ethnicity, N 215 
 
995 431 674 
 
81 46 84 45 
Tissue types Blood 
 
Blood Blood Blood 
 
Saliva Saliva Saliva Saliva 
PD status, N (%) 0 (0%) 
 
. . . 
 
81 (100%) 46 (100%) 0 (0%) 0 (0%) 
CHD status, N (%) . 
 
500 (50%) 215 (50%) 335 (50%) 
 
. . . . 
Age at blood draw, Mean (range) 68 (35-92) 
 
67 (50-79) 61 (50-79) 62 (50-79) 
 
69 (40-88) 69 (37-88) 69 (40-88) 67 (36-87) 
Female, N (%) 101 (47%) 
 
995 (100%) 431 (100%) 674 (100%) 37 (46%) 18 (39%) 38 (45%) 19 (42%) 
Coffee or tea (all types) (cup/day), Mean (SD) 3.6 (3.1) 
 
2.6 (1.9) 1.6 (1.5) 1.4 (1.5) 
 
1.8 (1.4) 1.4 (1.2) 2.6 (3.1) 2.2 (2.1) 
Ever coffee drinker, N (%) 187 (86%) 
 
786 (79%) 328 (77%) 360 (54%) 
 
64 (79%) 37 (80%) 74 (88%) 34 (76%) 
    Caffeinated coffee (cup/day), Mean (SD) 2.4 (2.7) 
 
2.3 (1.6) 1.9 (1.3) 1.5 (1.2) 
 
1.3 (1.1) 1.1 (1.2) 1.9 (1.9) 1.8 (1.8) 
    Decaffeinated coffee (cup/day), Mean (SD) 0.4 (0.9) 
 
. 0.5 (0.8) 0.5 (0.8) 
 
. . . . 
Ever Tea drinker, N (%) 169 (79%) 
 
. 36 (21%) 49 (19%) 
 
52 (68%) 20 (45%) 79 (94%) 33 (73%) 
    Caffeinated Tea (cup/day), Mean (SD) 1.0 (1.7) 
 
. 1.6 (0.6) 1.6 (0.6) 
 
0.8 (0.8) 0.5 (0.6) 0.9 (1.7) 0.6 (0.9) 
    Decaffeinated Tea (cup/day), Mean (SD) 0.3 (1.0) 
 
. . . 
 
. . . . 
Caffeinated soft drink (cup/day), Mean (SD) 0.6 (1.3) 
 
. . . 
 
. . . . 
Ever cigarette smoker, N (%) 129 (60%) 
 
461 (46%) 168 (39%) 353 (53%) 
 
29 (36%) 22 (48%) 47 (56%) 18 (40%) 
MHT ever use in female, N (%) 72 (71%)   441 (46%) 260 (62%) 330 (50%)   14 (64%) 8 (67%) 18 (56%) 4 (22%) 
NOTE: The percentage of ever coffee/tea drinkers was calculated after missing values were excluded. The mean and standard deviation (SD) of daily coffee/tea 
consumption is based on ever drinkers only. PD: Parkinson's Disease; CHD: Coronary Heart Disease; MHT: Menopausal Hormone Therapy. *Missing information (PEG1 
Ctrl Caucasian/WHI Caucasian/WHI Hispanic/ WHI African American/PEG2 PD Caucasian/PEG2 PD Hispanic/PEG2 Ctrl Caucasian/PEG2 Ctrl Hispanic): tea 
(N=0/./256/418/4/2/0/0), smoking (N=0/10/5/3/0/0/0/0), MHT (N=0/35/11/11/15/6/6/1).   
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Supplementary Table 4-S2. Crude and adjusted associations of coffee and 11 top-ranked CpGs in blood by subsets among PEG1 and 
WHI subjects 
Associations were evaluated with bi-weighted midcorrelations with or without adjustment for chronological age, gender, blood cell counts and 
smoking, stratified by race/ethnicity.  
      PEG1 Caucasian Ctrl (N=215) 
  
    
Unadjusted 
Adjusted for age, 
gender 
Adjusted for age, 
gender and cell counts 
Adjusted for age, 
gender, cell counts  
and smoking 
  CpG Gene biCor P-value biCor P-value biCor P-value biCor P-value 
1 cg21566642 intergenic, near ALPPL2 -0.35 1.79E-07 -0.31 1.34E-05 -0.29 3.60E-05 -0.16 2.49E-02 
2 cg20333292 GPR132 0.22 1.04E-03 0.25 3.50E-04 0.28 7.43E-05 0.24 7.22E-04 
3 cg21163128 BSCL2 0.27 6.52E-05 0.28 9.38E-05 0.28 6.77E-05 0.30 1.87E-05 
4 cg23303782 GRK5 0.25 2.16E-04 0.26 2.16E-04 0.29 3.55E-05 0.25 5.04E-04 
5 cg26105150 FSTL5 0.23 6.48E-04 0.25 5.52E-04 0.27 1.35E-04 0.23 1.25E-03 
6 cg19723563 PTHLH 0.16 1.55E-02 0.15 3.70E-02 0.17 2.14E-02 0.13 7.52E-02 
7 cg17928869 
intergenic, between EIF1 
and KRT42P 
0.18 7.33E-03 0.17 1.48E-02 0.23 1.35E-03 0.19 9.56E-03 
8 cg12866551 MALRD1 0.12 8.06E-02 0.16 2.96E-02 0.23 1.48E-03 0.21 3.44E-03 
9 cg15722372 PSMD8 0.18 9.28E-03 0.18 1.12E-02 0.20 4.55E-03 0.19 9.31E-03 
10 cg19974428 TMEM130 0.19 4.49E-03 0.21 4.11E-03 0.22 2.29E-03 0.16 2.85E-02 
11 cg15140902 FLJ22536 0.13 6.38E-02 0.13 6.98E-02 0.12 1.09E-01 0.10 1.83E-01 
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Supplementary Table 4-S2 (continued) 
      WHI Caucasian (N=995) 
  
    
Unadjusted Adjusted for age 
Adjusted for age and 
cell counts 
Adjusted for age,   
cell counts and 
smoking 
  CpG Gene biCor P-value biCor P-value biCor P-value biCor P-value 
1 cg21566642 intergenic, near ALPPL2 -0.14 1.72E-05 -0.13 2.41E-05 -0.14 1.34E-05 -0.09 3.31E-03 
2 cg20333292 GPR132 0.04 2.05E-01 0.04 1.95E-01 0.05 8.67E-02 0.06 8.21E-02 
3 cg21163128 BSCL2 0.10 2.24E-03 0.09 3.49E-03 0.10 2.40E-03 0.09 7.19E-03 
4 cg23303782 GRK5 0.05 1.11E-01 0.05 9.35E-02 0.06 4.37E-02 0.06 4.77E-02 
5 cg26105150 FSTL5 0.03 3.24E-01 0.04 1.88E-01 0.05 8.98E-02 0.05 1.31E-01 
6 cg19723563 PTHLH 0.06 6.86E-02 0.05 9.80E-02 0.07 2.20E-02 0.06 4.61E-02 
7 cg17928869 
intergenic, between EIF1 
and KRT42P 
0.05 1.12E-01 0.05 1.36E-01 0.08 1.17E-02 0.07 3.78E-02 
8 cg12866551 MALRD1 0.06 5.83E-02 0.05 9.93E-02 0.07 2.04E-02 0.07 2.71E-02 
9 cg15722372 PSMD8 0.04 1.77E-01 0.04 1.83E-01 0.05 9.92E-02 0.05 9.84E-02 
10 cg19974428 TMEM130 0.05 1.21E-01 0.05 9.58E-02 0.07 3.67E-02 0.06 4.46E-02 
11 cg15140902 FLJ22536 0.09 6.84E-03 0.09 3.67E-03 0.10 1.52E-03 0.08 8.09E-03 
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Supplementary Table 4-S2 (continued) 
      WHI Hispanic (N=431) 
  
    
Unadjusted Adjusted for age 
Adjusted for age and 
cell counts 
Adjusted for age,   
cell counts and 
smoking 
  CpG Gene biCor P-value biCor P-value biCor P-value biCor P-value 
1 cg21566642 intergenic, near ALPPL2 -0.08 1.10E-01 -0.08 1.06E-01 -0.07 1.28E-01 -0.02 7.14E-01 
2 cg20333292 GPR132 0.12 1.01E-02 0.12 1.32E-02 0.13 6.87E-03 0.12 1.36E-02 
3 cg21163128 BSCL2 0.09 6.01E-02 0.09 6.48E-02 0.09 6.23E-02 0.09 6.96E-02 
4 cg23303782 GRK5 0.07 1.39E-01 0.07 1.62E-01 0.09 6.39E-02 0.07 1.29E-01 
5 cg26105150 FSTL5 0.11 1.71E-02 0.11 2.26E-02 0.16 6.78E-04 0.16 9.35E-04 
6 cg19723563 PTHLH 0.14 3.62E-03 0.14 4.34E-03 0.13 5.22E-03 0.13 8.18E-03 
7 cg17928869 
intergenic, between EIF1 
and KRT42P 
0.10 3.77E-02 0.10 4.77E-02 0.11 2.11E-02 0.10 3.05E-02 
8 cg12866551 MALRD1 0.15 1.45E-03 0.14 4.42E-03 0.14 2.75E-03 0.15 2.18E-03 
9 cg15722372 PSMD8 0.08 1.09E-01 0.07 1.34E-01 0.10 4.67E-02 0.09 5.47E-02 
10 cg19974428 TMEM130 0.07 1.23E-01 0.08 9.41E-02 0.11 2.64E-02 0.10 3.67E-02 
11 cg15140902 FLJ22536 0.06 1.99E-01 0.07 1.42E-01 0.10 4.12E-02 0.09 6.58E-02 
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Supplementary Table 4-S2 (continued) 
      WHI African American (N=674) 
  
    
Unadjusted Adjusted for age 
Adjusted for age and 
cell counts 
Adjusted for age,   
cell counts and 
smoking 
  CpG Gene biCor P-value biCor P-value biCor P-value biCor P-value 
1 cg21566642 intergenic, near ALPPL2 -0.09 1.73E-02 -0.09 1.47E-02 -0.10 1.33E-02 -0.05 1.72E-01 
2 cg20333292 GPR132 0.06 1.13E-01 0.06 1.12E-01 0.07 9.10E-02 0.06 1.04E-01 
3 cg21163128 BSCL2 0.03 4.08E-01 0.03 3.91E-01 0.04 2.80E-01 0.04 2.82E-01 
4 cg23303782 GRK5 0.06 1.02E-01 0.06 9.94E-02 0.06 1.14E-01 0.06 1.22E-01 
5 cg26105150 FSTL5 0.02 5.42E-01 0.02 6.06E-01 0.02 5.45E-01 0.02 5.45E-01 
6 cg19723563 PTHLH 0.09 2.00E-02 0.09 2.16E-02 0.08 3.77E-02 0.08 4.43E-02 
7 cg17928869 
intergenic, between EIF1 
and KRT42P 
0.06 1.19E-01 0.06 1.17E-01 0.05 1.93E-01 0.05 2.05E-01 
8 cg12866551 MALRD1 0.03 5.03E-01 0.03 4.27E-01 0.03 4.21E-01 0.03 4.72E-01 
9 cg15722372 PSMD8 0.11 3.09E-03 0.11 3.19E-03 0.11 4.94E-03 0.10 7.21E-03 
10 cg19974428 TMEM130 0.07 5.44E-02 0.07 6.55E-02 0.07 5.55E-02 0.07 7.63E-02 
11 cg15140902 FLJ22536 0.09 2.47E-02 0.09 2.51E-02 0.09 1.72E-02 0.09 2.47E-02 
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Supplementary Table 4-S3. Associations of coffee and 11 top-ranked CpGs in blood (Table 1a, without smoking adjustment) by gender 
in the PEG study 
Associations were evaluated with bi-weighted midcorrelations with adjustment for chronological age and blood cell counts, stratified by gender.  
      PEG1 Caucasian Ctrl  
  
    
All, adjusted for age, 
gender and cell counts 
(N=215) 
Male, adjusted for age 
and cell counts 
(N=114) 
Female, adjusted for 
age and cell counts 
(N=101) 
  CpG Gene biCor P-value biCor P-value biCor P-value 
1 cg21566642 intergenic, near ALPPL2 -0.29 3.60E-05 -0.29 1.51E-03 -0.26 9.52E-03 
2 cg20333292 GPR132 0.28 7.43E-05 0.31 6.63E-04 -0.01 9.60E-01 
3 cg21163128 BSCL2 0.28 6.77E-05 0.38 3.48E-05 0.15 1.30E-01 
4 cg23303782 GRK5 0.29 3.55E-05 0.41 6.19E-06 -0.07 5.05E-01 
5 cg26105150 FSTL5 0.27 1.35E-04 0.27 3.80E-03 0.18 7.45E-02 
6 cg19723563 PTHLH 0.17 2.14E-02 0.23 1.20E-02 0.10 3.40E-01 
7 cg17928869 
intergenic, between EIF1 
and KRT42P 
0.23 1.35E-03 0.24 9.19E-03 0.19 5.11E-02 
8 cg12866551 MALRD1 0.23 1.48E-03 0.26 4.45E-03 0.02 8.30E-01 
9 cg15722372 PSMD8 0.20 4.55E-03 0.27 3.60E-03 -0.01 8.91E-01 
10 cg19974428 TMEM130 0.22 2.29E-03 0.35 1.24E-04 -0.04 7.03E-01 
11 cg15140902 FLJ22536 0.12 1.09E-01 0.12 1.93E-01 0.05 5.88E-01 
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Supplementary Table 4-S4. CpG sites influenced by both coffee consumption and smoking adjusted for chronological age, gender and 
blood cell counts  
List of CpGs associated with both coffee consumption and smoking (p-value threshold ≤10-7), (near) gene, chromosome, and CpG island they 
are located in, gene region, (Stouffer's test) Z-value and p-value from meta-analysis for coffee-DNAm and smoking-DNAm associations 
separately and combined.  
              Coffee and Smoking Coffee Smoking 
  CpG Gene Chr. Position(bp)
a 
 
Relation to 
UCSC CpG 
Island 
UCSC 
RefGene 
Group
b
 
meta.
Z 
meta. 
Pvalue 
meta.
Z 
meta. 
Pvalue 
meta. 
Z 
meta. 
Pvalue 
1 cg21566642 
intergenic, 
near ALPPL2 
2 233284661 Island 
 
-19.27 <4.00E-16 -6.26 3.73E-10 -20.98 <4.00E-16 
2 cg05951221 
 
2 233284402 Island 
 
-16.52 <4.00E-16 -4.33 1.50E-05 -19.03 <4.00E-16 
3 cg05575921 AHRR 5 373378 N_Shore Body -16.79 <4.00E-16 -4.24 2.24E-05 -19.51 <4.00E-16 
4 cg06644428 
 
2 233284112 Island 
 
-12.22 <4.00E-16 -4.07 4.63E-05 -13.21 <4.00E-16 
5 cg12803068 MYO1G 7 45002919 S_Shore Body 8.42 <4.00E-16 4.04 5.42E-05 7.87 3.55E-15 
6 cg01940273 
 
2 233284934 Island 
 
-12.87 <4.00E-16 -3.46 5.42E-04 -14.74 <4.00E-16 
7 cg23576855 AHRR 5 373299 N_Shore Body -8.33 <4.00E-16 -3.30 9.68E-04 -8.48 <4.00E-16 
8 cg06126421 
 
6 30720080 
  
-13.51 <4.00E-16 -3.29 9.95E-04 -15.82 <4.00E-16 
9 cg03636183 F2RL3 19 17000585 N_Shore Body -11.40 <4.00E-16 -3.26 1.13E-03 -12.87 <4.00E-16 
10 cg17287155 AHRR 5 393347 
 
Body -9.65 <4.00E-16 -2.94 3.28E-03 -10.70 <4.00E-16 
11 cg03604011 AHRR 5 400201 
 
Body 8.84 <4.00E-16 2.86 4.18E-03 9.64 <4.00E-16 
12 cg25189904 GNG12 1 68299493 S_Shore TSS1500 -8.93 <4.00E-16 -1.99 4.63E-02 -10.64 <4.00E-16 
13 cg13937905 RARG 12 53612551 N_Shore Body -8.14 4.44E-16 -3.39 6.96E-04 -8.12 4.44E-16 
14 cg04180046 MYO1G 7 45002736 Island Body 7.85 4.00E-15 3.84 1.24E-04 7.27 3.59E-13 
15 cg09935388 GFI1 1 92947588 Island Body -7.85 4.22E-15 -3.12 1.79E-03 -7.97 1.55E-15 
16 cg17924476 AHRR 5 323794 S_Shore Body 7.38 1.61E-13 3.19 1.43E-03 7.25 4.28E-13 
17 cg13193840 
 
2 233285289 Island 
 
-7.25 4.26E-13 -2.87 4.12E-03 -7.38 1.59E-13 
18 cg14656441 NDUFS5 1 39500070 
 
Body 7.23 4.68E-13 4.26 2.09E-05 5.98 2.29E-09 
19 cg19572487 RARA 17 38476024 S_Shore 5'UTR -7.12 1.08E-12 -1.09 2.76E-01 -8.98 <4.00E-16 
20 cg03329539 
 
2 233283329 N_Shore 
 
-7.11 1.20E-12 -1.75 7.99E-02 -8.30 <4.00E-16 
21 cg03991871 AHRR 5 368447 N_Shore Body -6.78 1.23E-11 -2.12 3.37E-02 -7.46 8.66E-14 
22 cg14675361 LMO7 13 76334583 
 
TSS1500 6.76 1.39E-11 3.91 9.37E-05 5.65 1.59E-08 
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23 cg23916896 AHRR 5 368804 N_Shore Body -6.73 1.68E-11 -1.53 1.27E-01 -7.99 1.33E-15 
24 cg21322436 CNTP2 7 145812842 N_Shore TSS1500 -6.72 1.87E-11 -2.68 7.40E-03 -6.82 9.14E-12 
25 cg07967717 CNR2 1 24229682 S_Shore 5'UTR 6.68 2.43E-11 4.46 8.06E-06 4.98 6.38E-07 
26 cg21806580 
 
5 18746010 
  
6.67 2.51E-11 3.76 1.67E-04 5.67 1.41E-08 
27 cg13039251 PDZD2 5 32018601 
 
Body 6.61 3.78E-11 2.74 6.11E-03 6.61 3.85E-11 
28 cg02714303 LMO7 13 76334728 
 
TSS200 6.53 6.75E-11 3.14 1.68E-03 6.09 1.15E-09 
29 cg10581837 LMO7 13 76334707 
 
TSS200 6.50 8.25E-11 3.39 6.98E-04 5.80 6.78E-09 
30 cg13185177 GP5 3 194119885 S_Shore 5'UTR 6.48 9.44E-11 2.91 3.66E-03 6.25 4.05E-10 
31 cg23288337 ECEL1P2 2 233250701 N_Shore Body 6.44 1.21E-10 3.26 1.13E-03 5.85 4.93E-09 
32 cg14179389 GFI1 1 92947961 Island Body -6.43 1.27E-10 -2.49 1.27E-02 -6.60 4.05E-11 
33 cg23480021 
 
3 22412746 N_Shore 
 
6.41 1.50E-10 1.47 1.43E-01 7.59 3.13E-14 
34 cg11660018 PRSS23 11 86510915 N_Shore TSS1500 -6.31 2.77E-10 -0.85 3.94E-01 -8.07 6.66E-16 
35 cg26242531 ZFYVE21 14 104190678 N_Shelf Body 6.30 2.96E-10 3.34 8.26E-04 5.57 2.59E-08 
36 cg00706683 ECEL1P2 2 233251030 N_Shore Body 6.24 4.43E-10 2.58 9.97E-03 6.25 4.23E-10 
37 cg03274391 
 
3 22413232 N_Shore 
 
6.23 4.65E-10 1.85 6.43E-02 6.96 3.37E-12 
38 cg08305533 SFI1 22 32007224 
 
Body 6.15 7.72E-10 3.98 6.90E-05 4.72 2.37E-06 
39 cg14753356 
 
6 30720108 
  
-6.14 8.03E-10 -0.32 7.46E-01 -8.37 <4.00E-16 
40 cg11492723 
 
3 16577697 
  
6.14 8.49E-10 4.24 2.27E-05 4.44 8.99E-06 
41 cg11165912 COL25A1 4 110220063 N_Shelf Body 6.13 8.84E-10 3.31 9.24E-04 5.36 8.55E-08 
42 cg17033047 KC3 1 111214851 N_Shore 3'UTR 6.11 9.86E-10 3.14 1.72E-03 5.51 3.63E-08 
43 cg11207515 CNTP2 7 146904205 
 
Body 6.05 1.44E-09 1.30 1.93E-01 7.25 4.06E-13 
44 cg19744173 FBLN7 2 112913178 N_Shelf Body 6.02 1.70E-09 3.21 1.34E-03 5.31 1.08E-07 
45 cg08940075 CNN3 1 95388680 N_Shelf Body 6.00 1.95E-09 3.33 8.61E-04 5.16 2.53E-07 
46 cg08606254 AHRR 5 323969 S_Shore Body 6.00 2.01E-09 2.45 1.45E-02 6.04 1.58E-09 
47 cg22947000 BCMO1 16 81272281 
 
TSS200 5.99 2.13E-09 3.49 4.87E-04 4.98 6.36E-07 
48 cg26601310 PRR5L 11 36397123 N_Shore 5'UTR 5.98 2.30E-09 4.45 8.78E-06 4.00 6.21E-05 
49 cg18390495 DEFB132 20 239809 
 
Body 5.97 2.39E-09 3.09 2.03E-03 5.36 8.55E-08 
50 cg24227984 HDGF2 19 4474970 S_Shore Body 5.97 2.40E-09 3.45 5.63E-04 4.99 5.97E-07 
51 cg13008538 CARD11 7 3083741 
 
TSS200 5.97 2.41E-09 3.20 1.37E-03 5.24 1.62E-07 
52 cg00665106 
 
1 201515370 
  
5.97 2.43E-09 3.98 6.85E-05 4.46 8.34E-06 
53 cg15693572 
 
3 22412385 N_Shore 
 
5.95 2.64E-09 1.82 6.92E-02 6.60 4.09E-11 
54 cg21161138 AHRR 5 399360 
 
Body -5.92 3.15E-09 -0.95 3.40E-01 -7.42 1.14E-13 
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55 cg14027333 PRRT1 6 32116317 N_Shore 3'UTR 5.91 3.50E-09 2.53 1.15E-02 5.83 5.66E-09 
56 cg18961281 CARD11 7 3083773 
 
TSS200 5.90 3.69E-09 3.65 2.60E-04 4.69 2.76E-06 
57 cg21771528 
 
5 18745861 
  
5.89 3.82E-09 2.98 2.93E-03 5.36 8.47E-08 
58 cg07211476 
 
18 53448189 S_Shore 
 
5.86 4.64E-09 3.38 7.18E-04 4.90 9.40E-07 
59 cg11557553 AHRR 5 404996 
 
Body 5.85 4.97E-09 2.81 4.95E-03 5.46 4.75E-08 
60 cg04951293 
 
2 231688289 
  
5.85 4.99E-09 4.33 1.48E-05 3.94 8.22E-05 
61 cg02657160 CPOX 3 98311063 N_Shore Body -5.84 5.07E-09 -1.77 7.62E-02 -6.49 8.43E-11 
62 cg25485805 
 
3 13246862 S_Shore 
 
5.84 5.18E-09 3.68 2.30E-04 4.58 4.71E-06 
63 cg09570614 
 
2 112124380 
  
5.83 5.49E-09 3.52 4.31E-04 4.73 2.28E-06 
64 cg25520249 CYP2S1 19 41700269 S_Shore Body 5.82 5.80E-09 3.60 3.23E-04 4.64 3.51E-06 
65 cg14977938 ZFYVE21 14 104190829 N_Shelf Body 5.79 7.00E-09 3.11 1.84E-03 5.08 3.87E-07 
66 cg20495738 CAC1C 12 2338399 N_Shore Body 5.79 7.11E-09 3.04 2.36E-03 5.14 2.68E-07 
67 cg00911794 HIC1 17 1962132 Island 3'UTR 5.78 7.31E-09 1.93 5.31E-02 6.25 4.24E-10 
68 cg14120896 
 
19 56086441 N_Shelf 
 
5.77 7.92E-09 3.15 1.63E-03 5.01 5.43E-07 
69 cg19713851 ALPP 2 233246594 S_Shore 3'UTR -5.77 7.96E-09 -1.53 1.25E-01 -6.63 3.45E-11 
70 cg01692968 
 
9 108005349 N_Shore 
 
-5.75 9.01E-09 -0.72 4.74E-01 -7.41 1.23E-13 
71 cg13184736 GNG12 1 68299409 S_Shore TSS1500 -5.75 9.14E-09 -1.15 2.49E-01 -6.97 3.12E-12 
72 cg24145685 STK11 19 1227852 Island 3'UTR 5.74 9.53E-09 4.54 5.73E-06 3.58 3.44E-04 
73 cg14817490 AHRR 5 392920 
 
Body -5.73 9.77E-09 -1.17 2.43E-01 -6.94 3.86E-12 
74 cg09762515 CUX1 7 101556588 N_Shelf Body 5.73 1.01E-08 3.50 4.64E-04 4.60 4.22E-06 
75 cg23161492 ANPEP 15 90357202 N_Shore 5'UTR -5.72 1.05E-08 -1.01 3.12E-01 -7.08 1.40E-12 
76 cg08035323 
 
2 9843525 
  
5.72 1.08E-08 3.64 2.73E-04 4.45 8.77E-06 
77 cg06635952 ANXA4 2 70025869 
 
Body 5.70 1.22E-08 2.52 1.17E-02 5.53 3.12E-08 
78 cg23621097 HIC1 17 1962236 Island 3'UTR 5.69 1.28E-08 2.75 5.96E-03 5.29 1.19E-07 
79 cg25800753 
 
10 94891725 
  
5.67 1.45E-08 3.96 7.46E-05 4.05 5.04E-05 
80 cg06885459 MCF2L 13 113689728 S_Shore Body 5.66 1.48E-08 3.76 1.73E-04 4.25 2.10E-05 
81 cg17272563 PRRT1 6 32116548 N_Shore 3'UTR 5.66 1.48E-08 2.82 4.75E-03 5.19 2.14E-07 
82 cg05768005 C17orf59 17 8094486 S_Shore TSS1500 5.66 1.49E-08 3.65 2.67E-04 4.36 1.28E-05 
83 cg04961225 
 
12 91332479 
  
5.66 1.55E-08 3.65 2.58E-04 4.34 1.40E-05 
84 cg05156137 RCAN1 21 35898975 
 
5'UTR 5.64 1.69E-08 2.64 8.19E-03 5.33 9.60E-08 
85 cg04912316 FAM100B 17 74266324 
 
Body -5.64 1.71E-08 -2.96 3.03E-03 -5.01 5.44E-07 
86 cg04737759 
 
6 155253937 
  
5.61 1.98E-08 3.41 6.44E-04 4.53 6.01E-06 
78 
 
87 cg03008815 RPS6KL1 14 75372636 
 
3'UTR 5.61 2.02E-08 3.58 3.40E-04 4.35 1.35E-05 
88 cg19325791 
 
17 46560683 
  
5.58 2.41E-08 3.34 8.39E-04 4.55 5.32E-06 
89 cg14397231 
 
4 124940041 
  
5.57 2.62E-08 2.42 1.54E-02 5.45 5.11E-08 
90 cg25949550 CNTP2 7 145814306 S_Shore Body -5.55 2.78E-08 -0.09 9.25E-01 -7.76 8.44E-15 
91 cg02612963 ZNF483 9 114287383 Island TSS200 5.55 2.81E-08 3.48 5.10E-04 4.38 1.20E-05 
92 cg24994127 RALGAPA2 20 20433328 Island Body 5.54 2.98E-08 3.83 1.30E-04 4.01 6.03E-05 
93 cg01352586 
 
1 202995473 Island 
 
5.53 3.25E-08 4.30 1.69E-05 3.51 4.41E-04 
94 cg11902777 AHRR 5 368843 N_Shore Body -5.51 3.50E-08 -1.43 1.51E-01 -6.36 1.96E-10 
95 cg09069072 TMEM51 1 15482753 S_Shore 5'UTR -5.50 3.76E-08 -2.83 4.65E-03 -4.95 7.39E-07 
96 cg27178191 SLC4A8 12 51819149 Island Body 5.50 3.84E-08 2.99 2.79E-03 4.79 1.71E-06 
97 cg18747408 
 
10 130841097 
  
5.50 3.84E-08 3.06 2.20E-03 4.71 2.44E-06 
98 cg23771366 PRSS23 11 86510998 N_Shore TSS1500 -5.50 3.89E-08 -0.41 6.82E-01 -7.36 1.82E-13 
99 cg02152819 
 
2 232258417 N_Shore 
 
5.49 4.02E-08 2.82 4.84E-03 4.95 7.56E-07 
100 cg25955180 PRRT1 6 32116538 N_Shore 3'UTR 5.48 4.23E-08 2.47 1.35E-02 5.28 1.28E-07 
101 cg15037583 MACROD1 11 63767176 Island Body 5.48 4.28E-08 3.49 4.87E-04 4.26 2.04E-05 
102 cg19974428 TMEM130 7 98468047 Island TSS1500 5.47 4.42E-08 4.65 3.34E-06 3.09 1.99E-03 
103 cg07178945 FGF23 12 4488800 
 
5'UTR 5.47 4.58E-08 2.11 3.49E-02 5.62 1.89E-08 
104 cg13167816 FITM1 14 24601808 S_Shore Body 5.46 4.64E-08 3.26 1.10E-03 4.46 8.01E-06 
105 cg03489965 LOC390594 15 65368982 N_Shore TSS200 5.45 4.94E-08 1.47 1.41E-01 6.24 4.34E-10 
106 cg08553467 C3orf27 3 128292922 
 
5'UTR 5.45 4.99E-08 3.77 1.63E-04 3.94 8.17E-05 
107 cg00138101 HIC1 17 1961109 Island Body 5.45 5.14E-08 3.53 4.16E-04 4.17 3.01E-05 
108 cg25474399 MYOM1 18 3067624 S_Shore Body 5.44 5.23E-08 2.58 9.83E-03 5.12 3.12E-07 
109 cg12549300 
 
13 113594776 N_Shelf 
 
5.44 5.39E-08 3.15 1.62E-03 4.54 5.67E-06 
110 cg24306779 MMP15 16 58060336 Island 1stExon 5.43 5.62E-08 2.88 3.95E-03 4.80 1.61E-06 
111 cg06213060 
 
3 16577726 
  
5.43 5.66E-08 3.30 9.65E-04 4.38 1.20E-05 
112 cg23973524 CRTC1 19 18873222 Island Body 5.43 5.67E-08 3.68 2.32E-04 4.00 6.44E-05 
113 cg04768713 ZNF701 19 53073334 Island TSS200 5.41 6.30E-08 3.57 3.54E-04 4.08 4.53E-05 
114 cg00336149 CAC1D 3 53700195 
 
Body 5.41 6.30E-08 2.67 7.54E-03 4.98 6.39E-07 
115 cg14422093 
 
1 227009245 
  
5.41 6.31E-08 3.33 8.65E-04 4.32 1.56E-05 
116 cg01207684 ADCY9 16 4103167 
 
Body -5.41 6.36E-08 -2.54 1.09E-02 -5.10 3.32E-07 
117 cg25197194 CCDC48 3 128758787 
 
3'UTR 5.40 6.59E-08 2.05 4.01E-02 5.59 2.31E-08 
118 cg08229199 GPR135 14 59932289 S_Shore TSS1500 5.40 6.65E-08 3.38 7.12E-04 4.25 2.12E-05 
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119 cg20431135 MFAP4 17 19290762 
 
TSS1500 5.39 7.17E-08 3.71 2.06E-04 3.91 9.38E-05 
120 cg13015908 
 
21 34481860 
  
5.38 7.41E-08 4.12 3.80E-05 3.49 4.82E-04 
121 cg17928869 
intergenic, 
between EIF1 
and KRT42P 
17 39822542 S_Shore 
 
5.38 7.48E-08 4.68 2.86E-06 2.93 3.42E-03 
122 cg13380502 GPR3 1 27718221 N_Shore TSS1500 5.38 7.66E-08 2.79 5.35E-03 4.82 1.46E-06 
123 cg14823389 
 
7 101398152 
  
5.37 8.07E-08 3.17 1.54E-03 4.42 9.86E-06 
124 cg00931843 TIAM2 6 155442993 
 
5'UTR 5.36 8.10E-08 2.58 9.81E-03 5.00 5.59E-07 
125 cg27067781 PRRT1 6 32116853 Island 3'UTR 5.36 8.17E-08 2.26 2.39E-02 5.33 1.01E-07 
126 cg16331679 C6orf103 6 146920166 Island 1stExon 5.36 8.29E-08 3.25 1.16E-03 4.33 1.48E-05 
127 cg19719391 
 
4 26789915 
  
5.36 8.40E-08 2.83 4.70E-03 4.75 2.03E-06 
128 cg02627991 
 
7 74032045 
  
5.35 8.62E-08 3.99 6.67E-05 3.58 3.39E-04 
129 cg23061027 PRRT1 6 32116207 N_Shore 3'UTR 5.35 8.69E-08 1.74 8.27E-02 5.83 5.41E-09 
130 cg26390660 
 
3 110344165 
  
5.35 8.99E-08 2.66 7.71E-03 4.90 9.77E-07 
131 cg05462761 PLEKHG5 1 6545157 Island 5'UTR 5.34 9.08E-08 3.44 5.83E-04 4.12 3.81E-05 
132 cg16705546 IRF8 16 85936666 S_Shelf Body 5.34 9.50E-08 3.24 1.20E-03 4.31 1.66E-05 
133 cg14488466 
 
9 93823465 
  
5.33 9.69E-08 2.43 1.50E-02 5.11 3.23E-07 
134 cg01899620 MCF2L 13 113689422 S_Shore Body 5.33 9.73E-08 3.63 2.79E-04 3.91 9.37E-05 
135 cg21878650 ADAMTS6 5 64558623 
 
Body 5.33 9.97E-08 3.13 1.73E-03 4.40 1.08E-05 
a
 Location is based on NCBI genome build 37.  
b
TSS: transcription start site, TSS500: within 1500 bps of a TSS, TSS200: within 200 bps of a TSS, UTR: untranslated region. 
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Supplementary Table 4-S5. Saliva results for the 5 top-ranked CpG sites in Table 1b and adjusted for chronological age, gender, race 
and smoking 
List of CpGs associated with coffee consumption, (near) gene, chromosome, and CpG island they are located in, gene region, a robust 
correlation coefficient (known as biweight midcorrelation) and p-value for daily coffee consumption (in last 12 months) and DNA methylation 
levels in the PEG2 study.    
 
       
PEG2 subjects, 
 adjusted for age, gender, race, 
smoking  
PEG2 subjects,  
adjusted for age, gender, race, 
smoking and PD status 
  CpG Gene Chr. 
Position 
(bp)
a 
 
Relation 
to UCSC 
CpG 
Island 
UCSC 
RefGene 
Group
b
 
biCor Z-value P-value biCor Z-value P-value 
1 cg21163128 BSCL2 11 62477362 Island TSS1500 -0.01 -0.09 9.26E-01 -0.03 -0.41 6.80E-01 
2 cg08119527 
Intergenic, 
near 
PODXL 
7 131340667 
  
-0.12 -2.00 4.65E-02 -0.07 -1.06 2.91E-01 
3 cg26331135 CNTN4 3 2144068 S_Shelf 5'UTR 0.00 -0.05 9.57E-01 0.03 0.42 6.75E-01 
4 cg20333292 GPR132 14 105532012 
 
TSS1500 0.03 0.53 5.93E-01 0.01 0.16 8.70E-01 
5 cg08311403 ROBO3 11 124735215 Island TSS200 -0.06 -1.00 3.18E-01 -0.06 -1.01 3.12E-01 
Abbreviations: BSCL2 (Berardinelli-Seip Congenital Lipodystrophy 2 (Seipin)), PODXL (Podocalyxin-Like), CNTN4, GPR132 (G Protein-Coupled 
Receptor 132), ROBO3 (Roundabout guidance receptor 3). 
a
Location is based on NCBI genome build 37.  
b
TSS: transcription start site, TSS500: within 1500 bps of a TSS, TSS200: within 200 bps of a TSS, UTR: untranslated region. 
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  (a)                                                                     (b)                                                                        (c) 
   
 
 
 
 
Supplementary Figure 4-S1. Q-Q plots of meta.Pvalue for the association between coffee consumption and each methylation site: a) 
adjust for age and gender (lambda=1.49); b) adjust for age, gender, and blood cell composition (lambda=2.24); c) adjust for age, 
gender, blood cell composition, and smoking (lambda=1.59). 
82 
 
5 Conclusion and Public Health Implications 
 
 
This dissertation examines the combined effect of lifestyle (i.e. coffee consumption and 
smoking) and genetic factors on the risk of Parkinson’s disease, as well as the association of 
coffee consumption with DNA methylation levels in both human blood and saliva tissues. In 
the first project, we found significant interactions between ADORA2A, CYP1A2 variants, and 
coffee consumptions in reducing PD risk. The inverse association between coffee and PD is 
strongest among homozygous minor-allele carriers, which supports the hypothesis that caffeine 
has a neuroprotective effect against PD.  Also, we suggest that survivor bias may affect results 
of studies that enroll prevalent PD cases. In the second project, we confirmed the inverse 
association of HLA-DRB1 variants with PD, and found this association was only observed in 
non-smokers. We provide the first evidence for the involvement of both HLA-DRB1 and 
smoking in the development of PD, possibly through neuroinflammation. In the third project, 
we found coffee affects DNA methylation levels in immune cells of the blood but not in saliva. 
And the coffee-associated methylation sites are linked to genes involved in lipid metabolism 
and immune response, suggesting possible mechanisms through which coffee consumption 
may be beneficial for health. We also provide support for the modified effect of 
postmenopausal estrogen use on coffee’s effect. 
Given the aging of the population worldwide, PD has a great impact not only on 
morbidity and mortality but on quality of life. Because the cause of idiopathic PD is unknown, 
proven ways to prevent the disease remain unclear. However, animal studies have showed that 
administration of caffeine or other adenosine A2A receptor antagonists (e.g. istradefylline) 
before the administration of PD-causing neurotoxin MPTP, significantly inhibited the MPTP-
induced loss of dopamine and dopaminergic neurons, suggesting that caffeine exposure in 
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early life could possibly reduce PD risk by inactivation of A2A receptors (Chen et al. 2001; 
Pierri et al. 2005). In addition, adenosine A2A receptor antagonist has been targeted for the 
non-dopaminergic treatment for PD in pharmacological studies, aiming to eliminate patients’ 
side effect from dopamine targeted therapy. A double-blind randomized clinical trial was 
conducted to examine istradefylline and found to significantly decrease the wearing-off time 
without introducing dyskinesia compared to levodopa (LeWitt et al. 2008). The continuously 
exploration of molecular mechanisms underlying the development of PD may help make 
better prevention and treatment strategies and reduce the suffering. 
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